Anti-CD3 binding agents and uses thereof

Abstract

Disclosed herein are an anti-CD3 molecules or functional variants thereof. Also disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating a disease or disorder using the aforesaid molecules.

Description

ANTI-CD3 BINDING AGENTS AND USES THEREOFCROSS-REFERENCE

[0001] This application claims the benefit of U.S. Provisional Application 63 / 736,889, filed December 20, 2024, the content of which is incorporated by reference herein in its entirety.BACKGROUND

[0002] Antibodies targeting the CD3 domain of the T cell receptor (TCR) complex have found use in different therapeutic areas such as oncology and immunity. An increasing number of them have been employed in an emerging drug class known as bispecific T cell engagers (TCE), these antibodies are characterised by the presence of targeting and effector arms. TCEs have made use of the anti-CD3 SP34, and its derivatives. However, SP34 has shown characteristics that are often associated with poor developability that have not been removed during humanisation. As such, there is a need to develop humanized anti-CD3 SP34.SUMMARY

[0003] Provided herein, in some embodiments, is a molecule comprising an antigen binding domain that binds to CD3, wherein the molecule comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises: a heavy chain complementarity determining region 1 (HCDR1) amino acid sequence of any one of SEQ ID NOs: 1-4, a heavy chain complementarity determining region 2 (HCDR2) amino acid sequence of any one of SEQ ID NOs: 5-12, and a heavy chain complementarity determining region 3 (HCDR3) amino acid sequence of SEQ ID NO: 13 or SEQ ID NO: 14. In some embodiments, the VL comprises: a light chain complementarity determining region 1 (LCDR1) amino acid sequence of any one of SEQ ID NOs: 15-19, or SEQ ID NO: 95, or SEQ ID NOs: 130-132, a light chain complementarity determining region 2 (LCDR2) amino acid sequence of any one of SEQ ID NOs: 20-26, or SEQ ID NO: 194, and a light chain complementarity determining region 3 (LCDR3) amino acid sequence of any one of SEQ ID NOs: 27-29. In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises -1-P93296.WO01 Final specification 19.12.2025a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 23, and a LCDR3 amino acid sequence of SEQ ID NO: 27; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 24, and a LCDR3 amino acid sequence of SEQ ID NO: 27; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 28; the VH comprises a-2-P93296.WO01 Final specification 19.12.2025HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 19, a LCDR2 amino acid sequence of SEQ ID NO: 25, and a LCDR3 amino acid sequence of SEQ ID NO: 27; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 29; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 10, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 28; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 12, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 24, and a LCDR3 amino acid sequence of SEQ ID NO: 27; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 4, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 19, a LCDR2 amino acid sequence of SEQ ID NO: 25, and a LCDR3 amino acid sequence of SEQ ID NO: 27; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 5, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL-3-P93296.WO01 Final specification 19.12.2025comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 26, and a LCDR3 amino acid sequence of SEQ ID NO: 27; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 24, and a LCDR3 amino acid sequence of SEQ ID NO: 29; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 9, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 3, a HCDR2 amino acid sequence of SEQ ID NO: 11, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 29; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29; the VH comprises a-4-P93296.WO01 Final specification 19.12.2025HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 5, and a HCDR3 amino acid sequence of SEQ ID NO: 13 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 15, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 13 and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 95, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27; the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 13; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 95, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 13; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 95, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 130, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or-5-P93296.WO01 Final specification 19.12.2025the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 131, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 130, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 131, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 132, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 132, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 130, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or-6-P93296.WO01 Final specification 19.12.2025the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 131, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 131, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 130, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or-7-P93296.WO01 Final specification 19.12.2025the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7 and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 131, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 130, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0004] In some embodiments, the VH further comprises: a heavy chain framework region 1 (HFWR1) amino acid sequence of SEQ ID NO: 30 or SEQ ID NO: 31; a heavy chain framework region 2 (HFWR2) amino acid sequence of any one of SEQ ID NOs: 32-35; a heavy chain framework region 3 (HFWR3) amino acid sequence of any one of SEQ ID NOs: 36-45; and a heavy chain framework region 4 (HFWR4) amino acid sequence of SEQ ID NO: 46.

[0005] In some embodiments, the VL further comprises: a light chain framework region 1 (LFWR1) amino acid sequence of SEQ ID NO: 47; a light chain framework region 2 (LFWR2) amino acid sequence of any one of SEQ ID NOs: 48-50 or SEQ ID NOs: 215-218; a light chain framework region 3 (LFWR3) amino acid sequence of any one of SEQ ID NOs: 51-54; and a light chain framework region 4 (LFWR4) amino acid sequence of SEQ ID NO: 55.

[0006] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NOs: 56-72, or SEQ ID NO: 181. In some embodiments, the VH comprises the sequence of any one of SEQ ID NOs: 56-72, or SEQ ID NO: 181.

[0007] In some embodiments, the VL comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NOs: 73-90, SEQ ID NOs: 133-180, or SEQ ID NOs: 182-193. In some embodiments, the VL comprises the sequence of any one of SEQ ID NOs: 73-90, SEQ ID NOs: 133-180, or SEQ ID NOs: 182-193.-8-P93296.WO01 Final specification 19.12.2025

[0008] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 77;

[0009] the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 76; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 84; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 78; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 86; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 76; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 80; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 79; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ -9-P93296.WO01 Final specification 19.12.2025ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 75; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 82; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 83; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 66 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 75; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 72 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 80; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 71 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 87; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 61 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 76; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 61 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 81 ; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 61 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 82; the -10-P93296.WO01 Final specification 19.12.2025VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 60 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 85; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 62 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 77; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 63 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 77; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 62 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 90; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 64 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 77; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 67 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 83; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 68 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 89; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 91 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 77; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 70 and the VL-11-P93296.WO01 Final specification 19.12.2025comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 77; the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 65 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 88; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 57 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 84; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 57 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 157; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 74; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 157; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 84; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 57 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 74; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 133;-12-P93296.WO01 Final specification 19.12.2025or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 134; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 135; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 136; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 137; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 216; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 138; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 139; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 140; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to -13-P93296.WO01 Final specification 19.12.2025the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 141 ; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 142; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 143; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 76; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 76; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 140; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 141; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 142; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least-14-P93296.WO01 Final specification 19.12.202599% sequence identity to the sequence of SEQ ID NO: 143; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 182; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 183; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 184; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 185; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 186; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 187; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 188; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 189; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at-15-P93296.WO01 Final specification 19.12.2025least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 190; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 191 ; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 192; or the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 193.

[0010] In some embodiments, the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 77;

[0011] the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 76; the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 84; the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 78; the VH comprises the sequence of SEQ ID NO: 58 and the VL comprising the sequence of SEQ ID NO: 86; the VH comprises the sequence of SEQ ID NO: 58 and the VL comprising the sequence of SEQ ID NO: 76; the VH comprises the sequence of SEQ ID NO: 58 and the VL comprising the sequence of SEQ ID NO: 80; the VH comprises the sequence of SEQ ID NO: 58 and the VL comprising the sequence of SEQ ID NO: 79; the VH comprises the sequence of SEQ ID NO: 58 and the VL comprising the sequence of SEQ ID NO: 75; the VH comprises the sequence of SEQ ID NO: 58 and the VL comprising the sequence of SEQ ID NO: 82; the VH comprises the sequence of SEQ ID NO: 58 and the VL comprising the sequence of SEQ ID NO: 83; the VH comprises the sequence of SEQ ID NO: 66 and the VL comprising the sequence of SEQ ID NO: 75; the VH comprises the sequence of SEQ ID NO: 72 and the VL comprising the sequence of SEQ ID NO: 80; the VH comprises the sequence of SEQ ID NO: 71 and the VL comprising the sequence of SEQ ID NO: 87; the VH-16-P93296.WO01 Final specification 19.12.2025comprises the sequence of SEQ ID NO: 61 and the VL comprising the sequence of SEQ ID NO: 76; the VH comprises the sequence of SEQ ID NO: 61 and the VL comprising the sequence of SEQ ID NO: 81; the VH comprises the sequence of SEQ ID NO: 61 and the VL comprising the sequence of SEQ ID NO: 82; the VH comprises the sequence of SEQ ID NO: 60 and the VL comprising the sequence of SEQ ID NO: 85; the VH comprises the sequence of SEQ ID NO: 62 and the VL comprising the sequence of SEQ ID NO: 77; the VH comprises the sequence of SEQ ID NO: 63 and the VL comprising the sequence of SEQ ID NO: 77; the VH comprises the sequence of SEQ ID NO: 62 and the VL comprising the sequence of SEQ ID NO: 90; the VH comprises the sequence of SEQ ID NO: 64 and the VL comprising the sequence of SEQ ID NO: 77; the VH comprises the sequence of SEQ ID NO: 67 and the VL comprising the sequence of SEQ ID NO: 83; the VH comprises the sequence of SEQ ID NO: 68 and the VL comprising the sequence of SEQ ID NO: 89; the VH comprises the sequence of SEQ ID NO: 91 and the VL comprising the sequence of SEQ ID NO: 77; the VH comprises the sequence of SEQ ID NO: 70 and the VL comprising the sequence of SEQ ID NO: 77; the VH comprises the sequence of SEQ ID NO: 65 and the VL comprising the sequence of SEQ ID NO: 88; the VH comprises the sequence of SEQ ID NO: 57 and the VL comprising the sequence of SEQ ID NO: 84; or the VH comprises the sequence of SEQ ID NO: 57 and the VL comprising the sequence of SEQ ID NO: 157; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 74; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 157; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 84; or the VH comprises the sequence of SEQ ID NO: 57 and the VL comprising the sequence of SEQ ID NO: 74; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 133; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 134; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 135; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 136; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 137; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 216; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 138; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 139; or the VH comprises the sequence of SEQ ID NO: 59 and the VL-17-P93296.WO01 Final specification 19.12.2025comprising the sequence of SEQ ID NO: 140; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 141; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 142; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 143; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 76; or the VH comprises the sequence of SEQ ID NO: 58 and the VL comprising the sequence of SEQ ID NO: 76; or the VH comprises the sequence of SEQ ID NO: 58 and the VL comprising the sequence of SEQ ID NO: 140; or the VH comprises the sequence of SEQ ID NO: 58 and the VL comprising the sequence of SEQ ID NO: 141; or the VH comprises the sequence of SEQ ID NO: 58 and the VL comprising the sequence of SEQ ID NO: 142; or the VH comprises the sequence of SEQ ID NO: 58 and the VL comprising the sequence of SEQ ID NO: 143; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 182; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 183; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 184; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 185; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 186; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 187; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 188; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 189; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 190; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 191; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 192; or the VH comprises the sequence of SEQ ID NO: 59 and the VL comprising the sequence of SEQ ID NO: 193.

[0012] In some embodiments, the antigen binding domain is a full antibody or antigen-binding fragment thereof, a bivalent antibody, bispecific antibody, or a biparatopic antibody. In some embodiments, the antigen binding domain is a Fab, F(ab’)2, Fv, a single chain Fv (scFv), a diabody, a single domain antibody, or a camelid antibody. In some embodiments, the antigen binding domain is a Fab or a scFv. In some embodiments, the antigen binding domain comprises one or more heavy chain constant regions selected from the group consisting of IgG 1 heavy-18-P93296.WO01 Final specification 19.12.2025chain constant region or functional fragment thereof, IgG2 heavy chain constant region or functional fragment thereof, IgG3 heavy chain constant region or functional fragment thereof, IgGAl heavy chain constant region or functional fragment thereof, IgGA2 heavy chain constant region or functional fragment thereof, IgG4 heavy chain constant region or functional fragment thereof, IgJ heavy chain constant region or functional fragment thereof, IgM heavy chain constant region or functional fragment thereof, IgD heavy chain constant region or functional fragment thereof, and IgE heavy chain constant region or functional fragment thereof.

[0013] In some embodiments, the one or more heavy chain constant regions comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NOs: 92-94. In some embodiments, the one or more heavy chain constant regions comprises the sequence of any one of SEQ ID NOs: 92-94.

[0014] In some embodiments, the antigen binding domain comprises a kappa light chain constant region or functional fragment thereof, a lambda light chain constant region or functional fragment thereof, or a combination thereof. In some embodiments, the lambda light chain constant region comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 91. In some embodiments, the lambda light chain constant region comprises the sequence of SEQ ID NO: 91.

[0015] Also disclosed herein, in some embodiments, is a molecule comprising a first heavy chain, a second heavy chain, and a first light chain, wherein the first heavy chain and the second heavy chain are non-contiguous, wherein: the first heavy chain comprises a heavy chain variable region (VH), comprising: a heavy chain complementarity determining region 1 (HCDR1) amino acid sequence of any one of SEQ ID NOs: 1-4, a heavy chain complementarity determining region 2 (HCDR2) amino acid sequence of any one of SEQ ID NOs: 5-12, and a heavy chain complementarity determining region 3 (HCDR3) amino acid sequence of SEQ ID NO: 13 or SEQ ID NO: 14; and the first light chain comprises a light chain variable region (VL).

[0016] In some embodiments, the VL comprises: a light chain complementarity determining region 1 (LCDR1) amino acid sequence of any one of SEQ ID NOs: 15-19 or 95 or SEQ ID NOs: 130-132, a light chain complementarity determining region 2 (LCDR2) amino acid sequence of any one of SEQ ID NOs: 20-26 or SEQ ID NO: 194, and a light chain complementarity determining region 3 (LCDR3) amino acid sequence of any one of SEQ ID NOs: 27-29. In some embodiments, the first heavy chain further comprises a first portion of a dimerization domain,-19-P93296.WO01 Final specification 19.12.2025wherein the first portion of a dimerization domain linked to the VH. In some embodiments, the second heavy chain further comprises a second portion of the dimerization domain. In some embodiments, the first portion of the dimerization domain and the second portion of the dimerization domain are dimerized. In some embodiments, the first heavy chain further comprises a heavy chain constant domain 1 (CHI) linked to the VH. In some embodiments, the CHI is linked to the C-terminus of the VH. In some embodiments, the first light chain further comprises a light chain constant domain (CL) linked to the VL. In some embodiments, the CL is linked to the C-terminus of the VL. In some embodiments, the first portion of the dimerization module is linked to C-terminus of the VH. In some embodiments, the first portion of the dimerization module is linked to C-terminus of the CHI. In some embodiments, the first portion of the dimerization module comprises a first immunoglobulin constant region (Fc region) and the second portion of the dimerization module comprises a second Fc region. In some embodiments, the first Fc region, the second Fc region, or a combination thereof is selected from the group consisting of an IgGl Fc region or a functional fragment thereof, an IgG2 Fc region or a functional fragment thereof, an IgG3 Fc region or a functional fragment thereof, an IgGAl Fc region or a functional fragment thereof, an IgGA2 Fc region or a functional fragment thereof, an IgG4 Fc region or a functional fragment thereof, an IgJ Fc region or a functional fragment thereof, an IgM Fc region or a functional fragment thereof, an IgD Fc region or a functional fragment thereof, and an IgE Fc region or a functional fragment thereof.

[0017] In some embodiments, the first Fc region, the second Fc region, or a combination thereof comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 93. In some embodiments, the first heavy chain comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NOs: 96-111.

[0018] In some embodiments, the first heavy chain comprises the sequence of any one of SEQ ID NOs: 96-111. In some embodiments, the second heavy chain comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NOs: 96-111. In some embodiments, the second heavy chain comprises the sequence of any one of SEQ ID NOs: 96-111. In some embodiments, the first light chain comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NOs: -20-P93296.WO01 Final specification 19.12.2025112-128, 144-156, or 195-206. In some embodiments, the first light chain comprises the sequence of any one of SEQ ID NOs: 112-128. In some embodiments, the molecule further comprises a second light chain. In some embodiments, the second light chain comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NOs: 112-128, 144-156, or 195- 206. In some embodiments, the second light chain comprises the sequence of any one of SEQ ID NOs: 112-128, 144-156, or 195-206.

[0019] In some embodiments, the molecule comprises: the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 113; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 114; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 115; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 116; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 113; the first heavy chain comprising a-21-P93296.WO01 Final specification 19.12.2025sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 117; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 118; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 119; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 120; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 121 ; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 98; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 119; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 99; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 117; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 100; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 129; the first heavy chain comprising a-22-P93296.WO01 Final specification 19.12.2025sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 101 ; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 113; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 101 ; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 126; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 101 ; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 120; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 102; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 127; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 103; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 104; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 103; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 128; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 104; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112; the first heavy chain comprising a-23-P93296.WO01 Final specification 19.12.2025sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 105; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 121 ; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 106; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 122; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 107; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 108; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 109; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 123; the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 110; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 124; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 111 ; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 125 or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 111 ; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 114; or the first heavy chain comprising a -24-P93296.WO01 Final specification 19.12.2025sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 111 ; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 144; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 125; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 144; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 114; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 111 ; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 125; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 145; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 146; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 147; or the first heavy chain comprising a -25-P93296.WO01 Final specification 19.12.2025sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 148; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 149; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 150; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 151 ; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 152; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 153; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 154; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 155; or the first heavy chain comprising a -26-P93296.WO01 Final specification 19.12.2025sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 113; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 97; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 113; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 97; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 153; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 97; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 154; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 97; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 155; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 97; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 156; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 195; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 196; or the first heavy chain comprising a -27-P93296.WO01 Final specification 19.12.2025sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 197; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 198; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 199; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 200; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 201 ; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 202; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 203; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 204; or the first heavy chain comprising a -28-P93296.WO01 Final specification 19.12.2025sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 205; or the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 206..

[0020] In some embodiments, the molecule comprises the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 112; the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 113; the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 114; the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 115; the first heavy chain comprising the sequence of SEQ ID NO: 58; and the first light chain comprising the sequence of SEQ ID NO: 116; the first heavy chain comprising the sequence of SEQ ID NO: 58; and the first light chain comprising the sequence of SEQ ID NO: 113; the first heavy chain comprising the sequence of SEQ ID NO: 58; and the first light chain comprising the sequence of SEQ ID NO: 117; the first heavy chain comprising the sequence of SEQ ID NO: 58; and the first light chain comprising the sequence of SEQ ID NO: 118; the first heavy chain comprising the sequence of SEQ ID NO: 58; and the first light chain comprising the sequence of SEQ ID NO: 119; the first heavy chain comprising the sequence of SEQ ID NO: 58; and the first light chain comprising the sequence of SEQ ID NO: 120; the first heavy chain comprising the sequence of SEQ ID NO: 58; and the first light chain comprising the sequence of SEQ ID NO: 121; the first heavy chain comprising the sequence of SEQ ID NO: 98; and the first light chain comprising the sequence of SEQ ID NO: 119; the first heavy chain comprising the sequence of SEQ ID NO: 99; and the first light chain comprising the sequence of SEQ ID NO: 117; the first heavy chain comprising the sequence of SEQ ID NO: 100; and the first light chain comprising the sequence of SEQ ID NO: 129; the first heavy chain comprising the sequence of SEQ ID NO: 101; and the first light chain comprising the sequence of SEQ ID NO: 113; the first heavy chain comprising the sequence of SEQ ID NO: 101; and the first light chain comprising the sequence of SEQ ID NO: 126; the first heavy chain comprising the-29-P93296.WO01 Final specification 19.12.2025sequence of SEQ ID NO: 101; and the first light chain comprising the sequence of SEQ ID NO: 120; the first heavy chain comprising the sequence of SEQ ID NO: 102; and the first light chain comprising the sequence of SEQ ID NO: 127; the first heavy chain comprising the sequence of SEQ ID NO: 103; and the first light chain comprising the sequence of SEQ ID NO: 112; the first heavy chain comprising the sequence of SEQ ID NO: 104; and the first light chain comprising the sequence of SEQ ID NO: 112; the first heavy chain comprising the sequence of SEQ ID NO: 103; and the first light chain comprising the sequence of SEQ ID NO: 128; the first heavy chain comprising the sequence of SEQ ID NO: 104; and the first light chain comprising the sequence of SEQ ID NO: 112; the first heavy chain comprising the sequence of SEQ ID NO: 105; and the first light chain comprising the sequence of SEQ ID NO: 121; the first heavy chain comprising the sequence of SEQ ID NO: 106; and the first light chain comprising the sequence of SEQ ID NO: 122; the first heavy chain comprising the sequence of SEQ ID NO: 107; and the first light chain comprising the sequence of SEQ ID NO: 112; the first heavy chain comprising the sequence of SEQ ID NO: 108; and the first light chain comprising the sequence of SEQ ID NO: 112; the first heavy chain comprising the sequence of SEQ ID NO: 109; and the first light chain comprising the sequence of SEQ ID NO: 123; the first heavy chain comprising the sequence of SEQ ID NO: 110; and the first light chain comprising the sequence of SEQ ID NO: 124; or the first heavy chain comprising the sequence of SEQ ID NO: 111; and the first light chain comprising the sequence of SEQ ID NO: 125; the first heavy chain comprising the sequence of SEQ ID NO: 111; and the first light chain comprising the sequence of SEQ ID NO: 114; or the first heavy chain comprising the sequence of SEQ ID NO: 111; and the first light chain comprising the sequence of SEQ ID NO: 144; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 125; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 144; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 114; or the first heavy chain comprising the sequence of SEQ ID NO: 111; and the first light chain comprising the sequence of SEQ ID NO: 125; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 145; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 146; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 147; or the -30-P93296.WO01 Final specification 19.12.2025first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 148; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 149; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 150; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 151; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 152; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 153; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 154; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 155; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 113; or the first heavy chain comprising the sequence of SEQ ID NO: 97; and the first light chain comprising the sequence of SEQ ID NO: 113; or the first heavy chain comprising the sequence of SEQ ID NO: 97; and the first light chain comprising the sequence of SEQ ID NO: 153; or the first heavy chain comprising the sequence of SEQ ID NO: 97; and the first light chain comprising the sequence of SEQ ID NO: 154; or the first heavy chain comprising the sequence of SEQ ID NO: 97; and the first light chain comprising the sequence of SEQ ID NO: 155; or the first heavy chain comprising the sequence of SEQ ID NO: 97; and the first light chain comprising the sequence of SEQ ID NO: 156; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 195; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 196; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 197; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 198; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 199; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 200; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 201; or the first heavy chain comprising the sequence -31-P93296.WO01 Final specification 19.12.2025of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 202; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 203; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 204; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 205; or the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 206.

[0021] In some embodiments, the molecule comprises: the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 113; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 114; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 115; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 116; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 113; the second heavy chain comprising a -32-P93296.WO01 Final specification 19.12.2025sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 117; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 118; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 119; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 120; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 121 ; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 98; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 119; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 99; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 117; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 100; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 129; the second heavy-33-P93296.WO01 Final specification 19.12.2025chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 101; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 113; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 101; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 126; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 101; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 120; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 102; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 127; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 103; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 104; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 103; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 128; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 104; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112;-34-P93296.WO01 Final specification 19.12.2025the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 105; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 121; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 106; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 122; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 107; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 108; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 109; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 123; the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 110; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 124; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 111; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 125, or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 111; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 114;-35-P93296.WO01 Final specification 19.12.2025or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 111; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 144; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 125; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 144; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 114; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 111; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 125; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 145; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 146; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 147;-36-P93296.WO01 Final specification 19.12.2025or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 148; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 149; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 150; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 151; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 152; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 153; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 154; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 155;-37-P93296.WO01 Final specification 19.12.2025or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 113; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 97; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 113; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 97; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 153; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 97; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 154; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 97; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 155; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 97; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 156; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 195; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 196;-38-P93296.WO01 Final specification 19.12.2025or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 197; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 198; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 199; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 200; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 201; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 202; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 203; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 204;-39-P93296.WO01 Final specification 19.12.2025or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 205; or the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 206.

[0022] In some embodiments, the molecule comprises: the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 112; the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 113; the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 114; the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 115; the second heavy chain comprising the sequence of SEQ ID NO: 58; and the second light chain comprising the sequence of SEQ ID NO: 116; the second heavy chain comprising the sequence of SEQ ID NO: 58; and the second light chain comprising the sequence of SEQ ID NO: 113; the second heavy chain comprising the sequence of SEQ ID NO: 58; and the second light chain comprising the sequence of SEQ ID NO: 117; the second heavy chain comprising the sequence of SEQ ID NO: 58; and the second light chain comprising the sequence of SEQ ID NO: 118; the second heavy chain comprising the sequence of SEQ ID NO: 58; and the second light chain comprising the sequence of SEQ ID NO: 119; the second heavy chain comprising the sequence of SEQ ID NO: 58; and the second light chain comprising the sequence of SEQ ID NO: 120; the second heavy chain comprising the sequence of SEQ ID NO: 58; and the second light chain comprising the sequence of SEQ ID NO: 121; the second heavy chain comprising the sequence of SEQ ID NO: 98; and the second light chain comprising the sequence of SEQ ID NO: 119; the second heavy chain comprising the sequence of SEQ ID NO: 99; and the second light chain comprising the sequence of SEQ ID NO: 117; the second heavy chain comprising the sequence of SEQ ID NO: 100; and the second light chain comprising the sequence of SEQ ID NO: 129; the second heavy chain comprising the sequence of SEQ ID NO: 101; and the second light chain comprising the sequence of SEQ ID NO: 113; the second heavy chain comprising the sequence of SEQ ID NO: 101; and the second -40-P93296.WO01 Final specification 19.12.2025light chain comprising the sequence of SEQ ID NO: 126; the second heavy chain comprising the sequence of SEQ ID NO: 101; and the second light chain comprising the sequence of SEQ ID NO: 120; the second heavy chain comprising the sequence of SEQ ID NO: 102; and the second light chain comprising the sequence of SEQ ID NO: 127; the second heavy chain comprising the sequence of SEQ ID NO: 103; and the second light chain comprising the sequence of SEQ ID NO: 112; the second heavy chain comprising the sequence of SEQ ID NO: 104; and the second light chain comprising the sequence of SEQ ID NO: 112; the second heavy chain comprising the sequence of SEQ ID NO: 103; and the second light chain comprising the sequence of SEQ ID NO: 128; the second heavy chain comprising the sequence of SEQ ID NO: 104; and the second light chain comprising the sequence of SEQ ID NO: 112; the second heavy chain comprising the sequence of SEQ ID NO: 105; and the second light chain comprising the sequence of SEQ ID NO: 121; the second heavy chain comprising the sequence of SEQ ID NO: 106; and the second light chain comprising the sequence of SEQ ID NO: 122; the second heavy chain comprising the sequence of SEQ ID NO: 107; and the second light chain comprising the sequence of SEQ ID NO: 112; the second heavy chain comprising the sequence of SEQ ID NO: 108; and the second light chain comprising the sequence of SEQ ID NO: 112; the second heavy chain comprising the sequence of SEQ ID NO: 109; and the second light chain comprising the sequence of SEQ ID NO: 123; the second heavy chain comprising the sequence of SEQ ID NO: 110; and the second light chain comprising the sequence of SEQ ID NO: 124; or the second heavy chain comprising the sequence of SEQ ID NO: 111; and the second light chain comprising the sequence of SEQ ID NO: 125 or the second heavy chain comprising the sequence of SEQ ID NO: 111; and the second light chain comprising the sequence of SEQ ID NO: 114; or the second heavy chain comprising the sequence of SEQ ID NO: 111; and the second light chain comprising the sequence of SEQ ID NO: 144; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 125; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 144; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 114; or the second heavy chain comprising the sequence of SEQ ID NO: 111; and the second light chain comprising the sequence of SEQ ID NO: 125; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 145; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising-41-P93296.WO01 Final specification 19.12.2025the sequence of SEQ ID NO: 146; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 147; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 148; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 149; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 150; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 151; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 152; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 153; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 154; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 155; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 113; or the second heavy chain comprising the sequence of SEQ ID NO: 97; and the second light chain comprising the sequence of SEQ ID NO: 113; or the second heavy chain comprising the sequence of SEQ ID NO: 97; and the second light chain comprising the sequence of SEQ ID NO: 153; or the second heavy chain comprising the sequence of SEQ ID NO: 97; and the second light chain comprising the sequence of SEQ ID NO: 154; or the second heavy chain comprising the sequence of SEQ ID NO: 97; and the second light chain comprising the sequence of SEQ ID NO: 155; or the second heavy chain comprising the sequence of SEQ ID NO: 97; and the second light chain comprising the sequence of SEQ ID NO: 156; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 195; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 196; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 197; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 198; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 199; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 200; or the second-42-P93296.WO01 Final specification 19.12.2025heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 201; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 202; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 203; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 204; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 205; or the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 206.

[0023] In some aspects the present disclosure provides a molecule comprising CDRs determined using the Kabat definition, as set out in Tables 1-5, 7 and 8. Also disclosed herein, in some embodiments, is a molecule comprising CDRs determined using the Chothia definition, as set out in Table 1A or Table IB. Also disclosed herein, in some embodiments, is a molecule comprising CDRs determined using the IMGT definition, as set out in Table 1A or Table IB. Also disclosed herein, in some embodiments, is a molecule comprising any one of the sequences from Tables 1-8.

[0024] Also disclosed herein, in some embodiments, is a pharmaceutical composition comprising the molecule described herein and a pharmaceutically acceptable excipient.

[0025] Also disclosed herein, in some embodiments, is a method for enhancing an immune response in a subject, comprising administering an effective amount of the described herein or the pharmaceutical composition described herein.

[0026] Also disclosed herein, in some embodiments, is a method for treating or preventing cancer in a subject, comprising administering an effective amount of the molecule described herein or the pharmaceutical composition described herein. In some embodiments, the cancer is selected from the group consisting of: pancreatic cancer, melanoma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine or endometrial cancer, cancer of the oral cavity or pharynx, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small bowel or appendix cancer, salivary gland cancer, thyroid gland cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, and cancer of hematological tissues.-43-P93296.WO01 Final specification 19.12.2025INCORPORATION BY REFERENCE

[0027] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.BRIEF DESCRIPTION OF THE DRAWINGS

[0028] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

[0029] FIGs. 1A-1B illustrate VH (FIG. 1A) and VL (FIG. IB) of parental antibody SP34_006 and toggle positions.

[0030] FIG. 2 illustrates quantification anti-Fc staining in SP34_006 parental antibody, VH library, VL library, and nontransfected HEK cells.

[0031] FIG. 3 illustrates a schematic of antibody selection.

[0032] FIGs. 4A-C illustrate the affinity of exemplary anti-CD3 molecules to human CD3 determined by ELISA. FIG. 4A illustrates the affinity of exemplary molecules IgG_083, IgG_084, IgG_085, and IgG_086. FIG. 4B illustrates the affinity of exemplary molecules IgG_087, IgG_088, IgG_089, IgG_090, IgG_092, IgG_093, IgG_095, IgG_096, IgG_097, and IgG_098. FIG. 4C illustrates the affinity of exemplary molecules IgG_099, IgG_100, IgG_101, IgG_102, IgG_103, IgG_104, IgG_105, IgG_106, IgG_107, IgG_108, and IgG_123.

[0033] FIGs. 5A-C illustrate the affinity of exemplary anti-CD3 molecules to cynomolgus CD3 determined by ELISA. FIG. 5A illustrates the affinity of exemplary molecules IgG_083, IgG_084, IgG_085, and IgG_086. FIG. 5B illustrates the affinity of exemplary molecules IgG_087, IgG_088, IgG_089, IgG_090, IgG_092, IgG_093, IgG_095, IgG_096, IgG_097, and IgG_098. FIG. 5C illustrates the affinity of exemplary molecules IgG_099, IgG_100, IgG_101, IgG_102, IgG_103, IgG_104, IgG_105, IgG_106, IgG_107, IgG_108, and IgG_123.

[0034] FIG. 6A-C illustrate the polyreactivity of exemplary anti-CD3 molecules as determined by binding to double stranded (ds) DNA measured by ELISA. FIG. 6A illustrates the polyreactivity of exemplary molecules IgG_083, IgG_084, IgG_085, IgG_086, IgG_087, IgG_088, and IgG_089. FIG. 6B illustrates the polyreactivity of exemplary molecules IgG_090,-44-P93296.WO01 Final specification 19.12.2025IgG_092, IgG_093, IgG_095, IgG_096, IgG_097, IgG_098, IgG _099, and IgG_100. FIG. 6C illustrates the polyreactivity of exemplary molecules IgG_101, IgG_102, IgG_103, IgG_104, IgG_105, IgG_106, IgG_107, IgG_108, and IgG_123.

[0035] FIG. 7A-C illustrate the polyreactivity of exemplary anti-CD3 molecules as determined by binding to insulin measured by ELISA. FIG. 7A illustrates the polyreactivity of exemplary molecules IgG_083, IgG_084, IgG_085, IgG_086, IgG_087, IgG_088, and IgG_089. FIG. 7B illustrates the polyreactivity of exemplary molecules IgG_090, IgG_092, IgG_093, IgG_095, IgG_096, IgG_097, IgG_098, IgG_099, and IgG_100. FIG. 7C illustrates the polyreactivity of exemplary molecules IgG_101, IgG_102, IgG_103, IgG_104, IgG_105, IgG_106, IgG_107, IgG_108, and IgG_123.

[0036] FIG. 8A-C illustrate the activity profile of exemplary anti-CD3 molecules determined by Jurkat T cell reporter assay. FIG. 8A illustrates the activity profile of exemplary molecules IgG_083, IgG_084, IgG_085, IgG_086, IgG_087, and IgG_088. FIG. 8B illustrates the activity profile of exemplary molecules IgG_089, IgG_090, IgG_092, IgG_093, IgG_095, IgG_096, IgG_097, and IgG_098. FIG. 8C illustrates the activity profile of exemplary molecules IgG _099, IgG_100, IgG_102, and IgG_123.

[0037] FIG. 9 illustrates the AC-SINS plasmon wavelength shifts for exemplary anti-CD3 molecules, including hSP34 (control), IgG_088, IgG_089, IgG_093 and IgG_123, IgG_078, IgG_083, IgG_084, IgG_085, IgG_086, IgG_087, IgG_090, IgG_092, IgG_095, IgG_097, IgG_098, IgG_099, IgG_100, IgG_102, IgG_109, IgG.HO, IgG_118, IgG_119, IgG_125, IgG_126, IgG_127 and parental control SP34_006 IgG.

[0038] FIG. 10A-B illustrate the expression levels and activity profiles of exemplary anti-CD3 molecules. FIG. 10A illustrates expression levels for IgG 187, IgG 204, IgG 182, IgG 183, IgG 189 and IgG 201. FIG. 10B illustrates the expression titers of different molecules, including IgG 201, IgG 204, IgG 205, IgG 206, IgG 207, IgG 208, IgG 209, IgG 210, IgG 211, IgG 212, IgG 213, IgG 214, IgG 215, IgG 216, IgG 217, and IgG 218.

[0039] FIG. 11 illustrates AC-SINS profiles for IgG 201, IgG 204, IgG 205, IgG 206, IgG 207, IgG 208, IgG 209, IgG 210, IgG 211, IgG 212, IgG 213, IgG 214, IgG 215, IgG 216, IgG 217, and IgG 218, compared to controls (mAB-3 and mAB-6).

[0040] FIG. 12 illustrates the Jurkat activity assay profile for different molecules, including IgG 201, IgG 204 (hSP34 control), IgG 205, IgG 206, IgG 207, IgG 208, IgG 209, IgG 210, IgG 211, IgG 212, IgG 213, IgG 214, IgG 215, IgG 216, IgG 217, and IgG 218.-45-P93296.WO01 Final specification 19.12.2025

[0041] FIGs 13A-B illustrate the expression profiles and AC-SINS profiles for exemplary molecules. 13A illustrates the expression profile as yield in mg / L for different molecules, including IgG 201, IgG 204 (hSP34 control), IgG 212, IgG 213, IgG 254, IgG 255, IgG 256, IgG257, IgG 258, IgG 259, IgG 260, IgG 261, IgG 262, IgG 263, IgG 264, IgG 265, IgG 266, IgG 267, IgG 268, and IgG 269.

[0042] FIG. 13B illustrates AC-SINS profiles for IgG 201, IgG 204 (hSP34 control), IgG 212, IgG 213, IgG 254, IgG 255, IgG 256, IgG 257, IgG 258, IgG 259, IgG 260, IgG 261, IgG 262, IgG 263, IgG 264, IgG 265, IgG 266, IgG 267, IgG 268, and IgG 269 compared to controls AC- mABl, AC-mAB2, AC-mAB3, AC-mAB4, AC-mAB5, and AC-mAB6.

[0043] FIG. 14A-D illustrate the Jurkat activity assay profile for different molecules, including IgG 201, IgG 204 (hSP34 control), IgG 212, IgG 213, IgG 254, IgG 255, IgG 256, IgG 257, IgG258, IgG 259, IgG 260, IgG 261, IgG 262, IgG 263, IgG 264, IgG 265, IgG 266, IgG 267, IgG 268 and IgG 269. FIG. 14A illustrates data for IgG_201 and IgG_204 (controls) compared with IgG_212, IgG_213, and IgG_254 - IgG_256. FIG. 14B illustrates data from testing FWR2 mutations. FIG. 14C illustrates data from testing VH3xVL3 combinations. FIG. 14D illustrated data from testing VH2xVL3 combinations.DETAILED DESCRIPTION

[0044] Provided herein, in some embodiments, is an antibody molecule or antigen-binding portion thereof that specifically binds to human CD3. In some embodiments, the antibody molecule antigen-binding portion thereof binds to CD3 variant SP34 or its derivatives. SP34 is a potent activator of T cells, it is species cross reactive. CD3 variant SP34 is murine in origin and its use requires prior humanization to avoid anti-drug antibodies (ADA)s.DEFINITION

[0045] Certain specific details of this description are set forth in order to provide a thorough understanding of various embodiments. However, one skilled in the art will understand that the present disclosure may be practiced without these details. In other instances, well-known structures have not been shown or described in detail to avoid unnecessarily obscuring descriptions of the embodiments.-46-P93296.WO01 Final specification 19.12.2025

[0046] Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense, that is, as “including, but not limited to.” Further, headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed disclosure.

[0047] As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. The use of the words “a” or “an” when used in conjunction with the term “comprising” herein may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”

[0048] It should also be noted that the term “or” is generally employed in its sense including “and / or” unless the content clearly dictates otherwise.

[0049] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below.

[0050] The term “about” when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20% or in some instances ±10%, or in some instances ±5%, or in some instances ±1%, or in some instances ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods. As used herein, “about” and “approximately” generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Exemplary degrees of error are within 20 percent (%), typically, within 10%, and more typically, within 5% of a given range of values.

[0051] “Antibody molecule” as used herein refers to a protein, e.g., an immunoglobulin chain or fragment thereof, comprising at least one immunoglobulin variable domain structure and / or sequence. An antibody molecule encompasses antibodies (e.g., full-length antibodies) and antibody fragments. In some embodiments, an antibody molecule comprises an antigen binding or functional fragment of a full length antibody, or a full length immunoglobulin chain. For example, a full-length antibody is an immunoglobulin (Ig) molecule (e.g., an IgG antibody) that is naturally occurring or formed by normal immunoglobulin gene fragment recombinatorial processes). In embodiments, an antibody molecule refers to an immunologically active, antigen-binding portion of an immunoglobulin molecule, such as an antibody fragment. An antibody fragment, e.g., -47-P93296.WO01 Final specification 19.12.2025functional fragment, is a portion of an antibody, e.g., Fab, Fab', F(ab')2, F(ab)2, variable fragment (Fv), domain antibody (dAb), or single chain variable fragment (scFv). A functional antibody fragment binds to the same antigen as that recognized by the intact (e.g., full-length) antibody. The terms “antibody fragment” or “functional fragment” also include isolated fragments consisting of the variable regions, such as the “Fv” fragments consisting of the variable regions of the heavy and light chains or recombinant single chain polypeptide molecules in which light and heavy variable regions are connected by a peptide linker (“scFv proteins”). In some embodiments, an antibody fragment does not include portions of antibodies without antigen binding activity, such as Fc fragments or single amino acid residues. Exemplary antibody molecules include full length antibodies and antibody fragments, e.g., dAb (domain antibody), single chain, Fab, Fab’, and F(ab’)2 fragments, and single chain variable fragments (scFvs). In some embodiments, the antibody molecule is an antibody mimetic. In some embodiments, the antibody molecule is, or comprises, an antibody-like framework or scaffold, such as, fibronectins, ankyrin repeats (e.g., designed ankyrin repeat proteins (DARPins)), avimers, affibody affinity ligands, anticalins, or affilin molecules.

[0052] As used herein, an “immunoglobulin variable domain sequence” refers to an amino acid sequence which can form the structure of an immunoglobulin variable domain. For example, the sequence may include all or part of the amino acid sequence of a naturally-occurring variable domain. For example, the sequence may or may not include one, two, or more N- or C-terminal amino acids, or may include other alterations that are compatible with formation of the protein structure.

[0053] In embodiments, an antibody molecule is monospecific, e.g., it comprises binding specificity for a single epitope. In some embodiments, an antibody molecule is multispecific, e.g., it comprises a plurality of immunoglobulin variable domain sequences, where a first immunoglobulin variable domain sequence has binding specificity for a first epitope and a second immunoglobulin variable domain sequence has binding specificity for a second epitope. In some embodiments, an antibody molecule is a bispecific antibody molecule. “Bispecific antibody molecule” as used herein refers to an antibody molecule that has specificity for more than one (e.g., two, three, four, or more) epitope and / or antigen.

[0054] “Antigen” (Ag) as used herein refers to a molecule that can provoke an immune response, e.g., involving activation of certain immune cells and / or antibody generation. Any macromolecule, including almost all proteins or peptides, can be an antigen. Antigens can also be derived from -48-P93296.WO01 Final specification 19.12.2025genomic recombinant or DNA. For example, any DNA comprising a nucleotide sequence or a partial nucleotide sequence that encodes a protein capable of eliciting an immune response encodes an “antigen.” In embodiments, an antigen does not need to be encoded solely by a full length nucleotide sequence of a gene, nor does an antigen need to be encoded by a gene at all. In embodiments, an antigen can be synthesized or can be derived from a biological sample, e.g., a tissue sample, a tumor sample, a cell, or a fluid with other biological components. As used, herein a “tumor antigen” or interchangeably, a “cancer antigen” includes any molecule present on, or associated with, a cancer, e.g., a cancer cell or a tumor microenvironment that can provoke an immune response. As used, herein an “immune cell antigen” includes any molecule present on, or associated with, an immune cell that can provoke an immune response.

[0055] The “antigen-binding site,” or “binding portion” of an antibody molecule refers to the part of an antibody molecule, e.g., an immunoglobulin (Ig) molecule, that participates in antigen binding. In embodiments, the antigen binding site is formed by amino acid residues of the variable (V) regions of the heavy (H) and light (L) chains. Three highly divergent stretches within the variable regions of the heavy and light chains, referred to as hypervariable regions, are disposed between more conserved flanking stretches called “framework regions,” (FRs). FRs are amino acid sequences that are naturally found between, and adjacent to, hypervariable regions in immunoglobulins. In embodiments, in an antibody molecule, the three hypervariable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three dimensional space to form an antigen-binding surface, which is complementary to the three-dimensional surface of a bound antigen. The three hypervariable regions of each of the heavy and light chains are referred to as “complementarity-determining regions,” or “CDRs.” The framework region and CDRs have been defined and described, e.g., in Kabat, E.A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242, and Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917. Each variable chain (e.g., variable heavy chain and variable light chain) is typically made up of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the amino acid order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. In some embodiment, CDRs and FRs are determined using Kabat, Chothia, IMGT, AbM, Contact, or any combination thereof.

[0056] The terms “polypeptide”, “peptide” and “protein” (if single chain) are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The terms -49-P93296.WO01 Final specification 19.12.2025also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. The polypeptide can be isolated from natural sources, can be a produced by recombinant techniques from a eukaryotic or prokaryotic host, or can be a product of synthetic procedures.

[0057] The terms “nucleic acid,” “nucleic acid sequence,” “nucleotide sequence,” or “polynucleotide sequence,” and “polynucleotide” are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. The polynucleotide may be either single-stranded or double- stranded, and if single-stranded may be the coding strand or non-coding (antisense) strand. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. The nucleic acid may be a recombinant polynucleotide, or a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which either does not occur in nature or is linked to another polynucleotide in a non-natural arrangement.

[0058] The term “isolated,” as used herein, refers to material that is removed from its original or native environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated by human intervention from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides could be part of a vector and / or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of the environment in which it is found in nature. An isolated polynucleotide (ribonucleic acid (RNA), deoxyribonucleic acid (DNA)), or polypeptide is free of the genes / nucleic acids or sequences / amino acids that flank it in its naturally-occurring state.

[0059] The compositions and methods of the present invention encompass polypeptides and nucleic acids having the sequences specified, or sequences substantially identical or similar thereto, e.g., sequences at least 80%, 85%, 90%, 95% identical or higher to the sequence specified. In the context of an amino acid sequence, the term “substantially identical” is used herein to refer to a first amino acid that contains a sufficient or minimum number of amino acid residues that are i) identical to, or ii) conservative substitutions of aligned amino acid residues in a second amino -50-P93296.WO01 Final specification 19.12.2025acid sequence such that the first and second amino acid sequences can have a common structural domain and / or common functional activity. For example, amino acid sequences that contain a common structural domain having at least about 80%, 85%, 90%. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% 99%, 99.5%, 99.9%, or 100% sequence identity to a reference sequence, e.g., a sequence provided herein. In the context of nucleotide sequence, the term “substantially identical” is used herein to refer to a first nucleic acid sequence that contains a sufficient or minimum number of nucleotides that are identical to aligned nucleotides in a second nucleic acid sequence such that the first and second nucleotide sequences encode a polypeptide having common functional activity, or encode a common structural polypeptide domain or a common functional polypeptide activity. For example, nucleotide sequences having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% 99%, 99.5%, 99.9%, or 100% sequence identity to a reference sequence, e.g., a sequence provided herein.

[0060] The term “variant” refers to a polypeptide that has a substantially identical amino acid sequence to a reference amino acid sequence, or is encoded by a substantially identical nucleotide sequence. In some embodiments, the variant is a functional variant.

[0061] The term “functional variant” refers to a polypeptide that has a substantially identical amino acid sequence to a reference amino acid sequence, or is encoded by a substantially identical nucleotide sequence, and is capable of having one or more activities of the reference amino acid sequence.

[0062] The term “functional fragment” or “functional variant” refers to a polypeptide that has a partial amino acid sequence of a reference amino acid sequence, and is capable of having one or more activities of the reference amino acid sequence. In some embodiments, the functional fragment or functional variant comprises at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% 99%, 99.5%, or 99.9% amino acid sequence of a reference amino acid sequence. In some embodiments, the functional fragment or functional variant comprises an amino acid sequence that has at most 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acid deletion from the reference amino acid sequence. In some embodiments, the functional fragment or functional variant comprises an amino acid sequence that has at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, -51-P93296.WO01 Final specification 19.12.2025140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 350, 400, 450, or 500 amino acids of the reference amino acid sequence.

[0063] Calculations of homology or sequence identity between sequences (the terms are used interchangeably herein) are performed as follows. To determine the percent identity of two amino acid sequences, or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”).

[0064] The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) J. Mol. Biol. 48:444-453 ) algorithm which has been incorporated into the GAP program in the GCG software package (available at http: / / www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at http: / / www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A particularly preferred set of parameters (and the one that should be used unless otherwise specified) are a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.

[0065] The percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4: 11-17) which has been -52-P93296.WO01 Final specification 19.12.2025incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The nucleic acid and protein sequences described herein can be used as a “query sequence” to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to a nucleic acid molecule of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25:3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

[0066] It is understood that the molecules of the present invention may have additional conservative or non-essential amino acid substitutions, which do not have a substantial effect on their functions.

[0067] The term “amino acid” is intended to embrace all molecules, whether natural or synthetic, which include both an amino functionality and an acid functionality and capable of being included in a polymer of naturally-occurring amino acids. Exemplary amino acids include naturally- occurring amino acids; analogs, derivatives and congeners thereof; amino acid analogs having variant side chains; and all stereoisomers of any of any of the foregoing. As used herein the term “amino acid” includes both the D- or L- optical isomers and peptidomimetics.

[0068] A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

[0069] As used herein, the term “molecule” as used in, e.g., antibody molecule, cytokine molecule, receptor molecule, includes full-length, naturally-occurring molecules, as well as variants, e.g., -53-P93296.WO01 Final specification 19.12.2025functional variants (e.g., truncations, fragments, mutated (e.g., substantially similar sequences) or derivatized form thereof), so long as at least one function and / or activity of the unmodified (e.g., naturally-occurring) molecule remains.

[0070] As used herein, the term “mutation” refers to an alteration in the nucleotide sequence of the genome of an organism, virus, or extrachromosomal DNA. In some embodiments, the mutation may be a large-scale mutation, such as amplifications (or gene duplications) or repetitions of a chromosomal segment, deletions of large chromosomal regions, chromosomal rearrangements (e.g., chromosomal translocations, chromosomal inversions, non-homologous chromosomal crossover, and interstitial deletions), and loss of heterozygosity. In some embodiments, the mutation may be a small-scale mutation, such as insertions, deletions, and substitution mutations. As used herein, the term “substitution mutation” refers to the transition that exchange a single nucleotide for another.

[0071] As used herein, the term “Fc region” is used to define a C-terminal region of an immunoglobulin heavy chain. The “Fc region” may be a native sequence Fc region or a variant Fc region. Although the boundaries of the Fc region of an immunoglobulin heavy chain might vary, the human IgG heavy chain Fc region is usually defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof. The numbering of the residues in the Fc region is that of the EU index as in Kabat. The Fc region of an immunoglobulin generally comprises two constant domains, CH2 and CH3. As is known in the art, an Fc region can be present in dimer or monomeric form.

[0072] A “variable region” of an antibody refers to the variable region of the antibody light chain or the variable region of the antibody heavy chain, either alone or in combination. As known in the art, the variable regions of the heavy and light chain each consist of four framework regions (FRs) connected by three complementarity determining regions (CDRs) also known as hypervariable regions, contribute to the formation of the antigen binding site of antibodies. When choosing FR to flank CDRs, for example when humanizing or optimizing an antibody, FRs from antibodies which contain CDR sequences in the same canonical class are preferred.

[0073] As used herein the term “conservative substitution” refers to replacement of an amino acid with another amino acid which does not significantly deleteriously change the functional activity. A preferred example of a “conservative substitution” is the replacement of one amino acid with another amino acid which has a value > 0 in the following BLOSUM 62 substitution matrix (see Henikoff & Henikoff, 1992, PNAS 89: 10915-10919):-54-P93296.WO01 Final specification 19.12.2025A R N D C Q E G H I L K M F P S T W Y VA 4 -1 -2 -2 0 -1 -1 0 -2 -1 -1 -1 -1 -2 -1 1 0 -3 -2 0R -1 5 0 -2 -3 1 0 -2 0 -3 -2 2 -1 -3 -2 -1 -1 -3 -2 -3N -2 0 6 1 -3 0 0 0 1 -3 -3 0 -2 -3 -2 1 0 -4 -2 -3D -2 -2 1 6 -3 0 2 -1 -1 -3 -4 -1 -3 -3 -1 0 -1 -4 -3 -3C 0 -3 -3 -3 9 -3 -4 -3 -3 -1 -1 -3 -1 -2 -3 -1 -1 -2 -2 -1Q -1 1 0 0 -3 5 2 -2 0 -3 -2 1 0 -3 -1 0 -1 -2 -1 -2E -1 0 0 2 -4 2 5 -2 0 -3 -3 1 -2 -3 -1 0 -1 -3 -2 -2G 0 -2 0 -1 -3 -2 -2 6 -2 -4 -4 -2 -3 -3 -2 0 -2 -2 -3 -3H -2 0 1 -1 -3 0 0 -2 8 -3 -3 -1 -2 -1 -2 -1 -2 -2 2 -3I -1 -3 -3 -3 -1 -3 -3 -4 -3 4 2 -3 1 0 -3 -2 -1 -3 -1 3L -1 -2 -3 -4 -1 -2 -3 -4 -3 2 4 -2 2 0 -3 -2 -1 -2 -1 1K -1 2 0 -1 -3 1 1 -2 -1 -3 -2 5 -1 -3 -1 0 -1 -3 -2 -2M -1 -1 -2 -3 -1 0 -2 -3 -2 1 2 -1 5 0 -2 -1 -1 -1 -1 1F -2 -3 -3 -3 -2 -3 -3 -3 -1 0 0 -3 0 6 -4 -2 -2 1 3 -1P -1 -2 -2 -1 -3 -1 -1 -2 -2 -3 -3 -1 -2 -4 7 -1 -1 -4 -3 -2S 1 -1 1 0 -1 0 0 0 -1 -2 -2 0 -1 -2 -1 4 1 -3 -2 -2T 0 -1 0 -1 -1 -1 -1 -2 -2 -1 -1 -1 -1 -2 -1 1 5 -2 -2 0W -3 -3 -4 -4 -2 -2 -3 -2 -2 -3 -2 -3 -1 1 -4 -3 -2 11 2 -3Y -2 -2 -2 -3 -2 -1 -2 -3 2 -1 -1 -2 -1 3 -3 -2 -2 2 7 -1V 0 -3 -3 -3 -1 -2 -2 -3 -3 3 1 -2 1 -1 -2 -2 0 -3 -1 4

[0074] The term “monoclonal antibody” (Mab) refers to an antibody, or antigen-binding portion thereof, that is derived from a single copy or clone, including for example any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced. Preferably, a monoclonal antibody of the invention exists in a homogeneous or substantially homogeneous population.

[0075] A “humanized” antibody molecule refers to a form of non-human (for example, murine) antibody molecules, or antigen-binding portion thereof, that are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigenbinding subsequences of antibodies) that contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies may be human immunoglobulins (recipient antibody) in which residues from a CDR of the recipient are replaced by residues from a CDR of a non--55-P93296.WO01 Final specification 19.12.2025human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity.

[0076] The term “chimeric antibody” is intended to refer to an antibody molecule, or antigenbinding portion thereof, in which the variable region sequences are derived from one species and the constant region sequences are derived from another species, such as an antibody molecule in which the variable region sequences are derived from a mouse antibody and the constant region sequences are derived from a human antibody.

[0077] “Antibody-drug conjugate” and “immunoconjugate” refer to an antibody molecule, or antigen-binding portion thereof, including antibody derivatives that binds to CD3 and is conjugated to cytotoxic, cytostatic and / or therapeutic agents.

[0078] Antibody molecules of the invention, or antigen-binding portion thereof, can be produced using techniques well known in the art, for example recombinant technologies, phage display technologies, synthetic technologies or combinations of such technologies or other technologies readily known in the art.

[0079] The term “epitope” refers to that portion of a molecule capable of being recognized by and bound by an antibody molecule, or antigen-binding portion thereof, at one or more of the antibody molecule's antigen-binding regions. Epitopes can consist of defined regions of primary secondary or tertiary protein structure and includes combinations of secondary structural units or structural domains of the target recognised by the antigen binding regions of the antibody, or antigen-binding portion thereof. Epitopes can likewise consist of a defined chemically active surface grouping of molecules such as amino acids or sugar side chains and have specific three- dimensional structural characteristics as well as specific charge characteristics. The term “antigenic epitope” as used herein, is defined as a portion of a polypeptide to which an antibody molecule can specifically bind as determined by any method well known in the art, for example, by conventional immunoassays, antibody competitive binding assays or by x-ray crystallography or related structural determination methods (for example NMR).

[0080] The term “binding affinity” or “KD” refers to the dissociation rate of a particular antigenantibody interaction. The KD is the ratio of the rate of dissociation, also called the “off-rate (kOff)”, to the association rate, or “on-rate (kon)”. Thus, KD equals kOff / konand is expressed as a molar concentration (M). It follows that the smaller the KD, the stronger the affinity of binding. Therefore, a KD of 1 pM indicates weak binding affinity compared to a KD of 1 nM. KD values for antibodies can be determined using methods well established in the art. One method for-56-P93296.WO01 Final specification 19.12.2025determining the KD of an antibody is by using surface plasmon resonance (SPR), typically using a biosensor system such as a Biacore® system.

[0081] The phrase “effective amount” or “therapeutically effective amount” as used herein refers to an amount necessary (at dosages and for periods of time and for the means of administration) to achieve the desired therapeutic result. An effective amount is at least the minimal amount, but less than a toxic amount, of an active agent which is necessary to impart therapeutic benefit to a subject.

[0082] A “host cell” includes an individual cell or cell culture that can be or has been a recipient for vector(s) for incorporation of polynucleotide inserts. Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in genomic DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation. A host cell includes cells transfected in vivo with a polynucleotide(s) of this invention.

[0083] As used herein, “vector” means a construct, which is capable of delivering, and, preferably, expressing, one or more gene(s) or sequence(s) of interest in a host cell. Examples of vectors include, but are not limited to, viral vectors, naked DNA or RNA expression vectors, plasmid, cosmid or phage vectors, DNA or RNA expression vectors associated with cationic condensing agents, DNA or RNA expression vectors encapsulated in liposomes, and certain eukaryotic cells, such as producer cells.

[0084] The term “treating”, as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, delaying the progression of, delaying the onset of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term “treatment”, as used herein, unless otherwise indicated, refers to the act of treating as defined above. The term “treating” also includes adjuvant and neoadjuvant treatment of a subject. For the avoidance of doubt, reference herein to “treatment” includes reference to curative, palliative and prophylactic treatment. For the avoidance of doubt, references herein to “treatment” also include references to curative, palliative and prophylactic treatment.

[0085] It is understood that wherever embodiments are described herein with the language “comprising,” otherwise analogous embodiments described in terms of “consisting of’ and / or “consisting essentially of’ are also provided.Antibody Molecules-57-P93296.WO01 Final specification 19.12.2025

[0086] In some embodiments, the antibody molecule binds to a cancer antigen, e.g., a tumor antigen or a stromal antigen. In some embodiments, the cancer antigen is, e.g., a mammalian, e.g., a human, cancer antigen. In other embodiments, the antibody molecule binds to an immune cell antigen, e.g., a mammalian, e.g., a human, immune cell antigen. For example, the antibody molecule binds specifically to an epitope, e.g., linear or conformational epitope, on the cancer antigen or the immune cell antigen.

[0087] In some embodiments, an antibody molecule is a monospecific antibody molecule and binds a single epitope. E.g., a monospecific antibody molecule having a plurality of immunoglobulin variable domain sequences, each of which binds the same epitope.

[0088] In some embodiments, an antibody molecule comprises a diabody, and a single-chain molecule, as well as an antigen-binding fragment of an antibody (e.g., Fab, F(ab’)2, and Fv). For example, an antibody molecule can include a heavy (H) chain variable domain sequence (abbreviated herein as VH), and a light (E) chain variable domain sequence (abbreviated herein as VE). In some embodiments, an antibody molecule comprises or consists of a heavy chain and a light chain (referred to herein as a half antibody. In another example, an antibody molecule includes two heavy (H) chain variable domain sequences and two light (L) chain variable domain sequence, thereby forming two antigen binding sites, such as Fab, Fab’, F(ab’)2, Fc, Fd, Fd’, Fv, single chain antibodies (scFv for example), single variable domain antibodies, diabodies (Dab) (bivalent and bispecific), and chimeric (e.g., humanized) antibodies, which may be produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA technologies. These functional antibody fragments retain the ability to selectively bind with their respective antigen or receptor. Antibodies and antibody fragments can be from any class of antibodies including, but not limited to, IgG, IgA, IgM, IgD, and IgE, and from any subclass (e.g., IgGl, IgG2, IgG3, and IgG4) of antibodies. The preparation of antibody molecules can be monoclonal or polyclonal. An antibody molecule can also be a human, humanized, CDR-grafted, or in vitro generated antibody. The antibody can have a heavy chain constant region chosen from, e.g., IgGl, IgG2, IgG3, or IgG4. The antibody can also have a light chain chosen from, e.g., kappa or lambda. The term “immunoglobulin” (Ig) is used interchangeably with the term “antibody” herein.

[0089] Examples of antigen-binding fragments of an antibody molecule include: (i) a Fab fragment, a monovalent fragment consisting of the VE, VH, CL and CHI domains; (ii) a F(ab’)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the -58-P93296.WO01 Final specification 19.12.2025hinge region; (iii) a Fd fragment consisting of the VH and CHI domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a diabody (dAb) fragment, which consists of a VH domain; (vi) a camelid or camelized variable domain; (vii) a single chain Fv (scFv), see e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883); (viii) a single domain antibody. These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies.

[0090] Antibody molecules include intact molecules as well as functional fragments thereof. Constant regions of the antibody molecules can be altered, e.g., mutated, to modify the properties of the antibody (e.g., to increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, or complement function).

[0091] Antibody molecules can also be single domain antibodies. Single domain antibodies can include antibodies whose complementary determining regions are part of a single domain polypeptide. Examples include, but are not limited to, heavy chain antibodies, antibodies naturally devoid of light chains, single domain antibodies derived from conventional 4-chain antibodies, engineered antibodies and single domain scaffolds other than those derived from antibodies. Single domain antibodies may be any of the art, or any future single domain antibodies. Single domain antibodies may be derived from any species including, but not limited to mouse, human, camel, llama, fish, shark, goat, rabbit, and bovine. According to another aspect of the invention, a single domain antibody is a naturally occurring single domain antibody known as heavy chain antibody devoid of light chains. Such single domain antibodies are disclosed in WO 9404678, for example. For clarity reasons, this variable domain derived from a heavy chain antibody naturally devoid of light chain is known herein as a VHH or nanobody to distinguish it from the conventional VH of four chain immunoglobulins. Such a VHH molecule can be derived from antibodies raised in Camelidae species, for example in camel, llama, dromedary, alpaca and guanaco. Other species besides Camelidae may produce heavy chain antibodies naturally devoid of light chain; such VHHs are within the scope of the invention.

[0092] The VH and VL regions can be subdivided into regions of hypervariability, termed “complementarity determining regions” (CDR), interspersed with regions that are more conserved, termed “framework regions” (FR or FW).

[0093] The extent of the framework region and CDRs has been precisely defined by a number of methods (see, Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth -59-P93296.WO01 Final specification 19.12.2025Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242; Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917; and the AbM definition used by Oxford Molecular’s AbM antibody modeling software. See, generally, e.g., Protein Sequence and Structure Analysis of Antibody Variable Domains. In: Antibody Engineering Lab Manual (Ed.: Duebel, S. and Kontermann, R., Springer- Verlag, Heidelberg).

[0094] The terms “complementarity determining region,” and “CDR,” as used herein refer to the sequences of amino acids within antibody variable regions which confer antigen specificity and binding affinity. In general, there are three CDRs in each heavy chain variable region (HCDR1, HCDR2, HCDR3) and three CDRs in each light chain variable region (LCDR1, LCDR2, LCDR3).

[0095] The precise amino acid sequence boundaries of a given CDR can be determined using any of a number of known schemes, including those described by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5thEd. Public Health Service, National Institutes of Health, Bethesda, MD (“Kabat” numbering scheme), ALLazikani et al., (1997) JMB 273,927-948 (“Chothia” numbering scheme). As used herein, the CDRs defined according the “Chothia” number scheme are also sometimes referred to as “hypervariable loops.”

[0096] For example, under Kabat, the CDR amino acid residues in the heavy chain variable domain (VH) are numbered 31-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3); and the CDR amino acid residues in the light chain variable domain (VL) are numbered 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3). Under Chothia, the CDR amino acids in the VH are numbered 26-32 (HCDR1), 52-56 (HCDR2), and 95-102 (HCDR3); and the amino acid residues in VL are numbered 26-32 (LCDR1), 50-52 (LCDR2), and 91-96 (LCDR3).

[0097] Each VH and VL typically includes three CDRs and four FRs, arranged from aminoterminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

[0098] The antibody molecule can be a polyclonal or a monoclonal antibody.

[0099] The terms “monoclonal antibody” or “monoclonal antibody composition” as used herein refer to a preparation of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope. A monoclonal antibody can be made by hybridoma technology or by methods that do not use hybridoma technology (e.g., recombinant methods).

[0100] The antibody can be recombinantly produced, e.g., produced by phage display or by combinatorial methods, or by yeast display.-60-P93296.WO01 Final specification 19.12.2025

[0101] Phage display and combinatorial methods for generating antibodies are known in the art (as described in, e.g., Ladner et al. U.S. Patent No. 5,223,409; Kang et al. International Publication No. WO 92 / 18619; Dower et al. International Publication No. WO 91 / 17271; Winter et al. International Publication WO 92 / 20791; Markland et al. International Publication No. WO 92 / 15679; Breitling et al. International Publication WO 93 / 01288; McCafferty et al. International Publication No. WO 92 / 01047; Garrard et al. International Publication No. WO 92 / 09690; Ladner et al. International Publication No. WO 90 / 02809; Fuchs et al. (1991) Bio / Technology 9:1370- 1372; Hay et al. (1992) Hum Antibod Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275- 1281; Griffths et al. (1993) EMBO J 12:725-734; Hawkins et al. (1992) J Mol Biol 226:889-896; Clackson et al. (1991) Nature 352:624-628; Gram et al. (1992) PNAS 89:3576-3580; Garrad et al. (1991) Bio / Technology 9:1373-1377; Hoogenboom et al. (1991) Nuc Acid Res 19:4133-4137; and Barbas et al. (1991) PNAS 88:7978-7982, the contents of all of which are incorporated by reference herein).

[0102] The yeast display method for generating or identifying antibodies is known in the art, e.g., as described in Chao et al. (2006) Nature Protocols l(2):755-68, the entire contents of which is incorporated by reference herein.

[0103] In some embodiments, the antibody is a fully human antibody (e.g., an antibody made in a mouse which has been genetically engineered to produce an antibody from a human immunoglobulin sequence), or a non-human antibody, e.g., a rodent (mouse or rat), goat, primate (e.g., monkey), camel antibody. Preferably, the non-human antibody is a rodent (mouse or rat antibody). Methods of producing rodent antibodies are known in the art.

[0104] Human monoclonal antibodies can be generated using transgenic mice carrying the human immunoglobulin genes rather than the mouse system. Splenocytes from these transgenic mice immunized with the antigen of interest are used to produce hybridomas that secrete human mAbs with specific affinities for epitopes from a human protein (see, e.g., Wood et al. International Application WO 91 / 00906, Kucherlapati et al. PCT publication WO 91 / 10741; Lonberg et al. International Application WO 92 / 03918; Kay et al. International Application 92 / 03917; Lonberg, N. et al. 1994 Nature 368:856-859; Green, L.L. et al. 1994 Nature Genet. 7: 13-21; Morrison, S.L. et al.claims 1994 Proc. Natl. Acad. Sci. USA 81:6851-6855; Bruggeman et al. 1993 Year Immunol 7:33-40; Tuaillon et al. 1993 PNAS 90:3720-3724; Bruggeman et al. 1991 Eur J Immunol 21: 1323-1326).-61-P93296.WO01 Final specification 19.12.2025

[0105] An antibody molecule can be one in which the variable region, or a portion thereof, e.g., the CDRs, are generated in a non-human organism, e.g., a rat or mouse. Chimeric, CDR-grafted, and humanized antibodies are within the invention. Antibody molecules generated in a non-human organism, e.g., a rat or mouse, and then modified, e.g., in the variable framework or constant region, to decrease antigenicity in a human are within the invention.

[0106] An “effectively human” protein is a protein that does substantially not evoke a neutralizing antibody response, e.g., the human anti-murine antibody (HAMA) response. HAMA can be problematic in a number of circumstances, e.g., if the antibody molecule is administered repeatedly, e.g., in treatment of a chronic or recurrent disease condition. A HAMA response can make repeated antibody administration potentially ineffective because of an increased antibody clearance from the serum (see, e.g., Saleh et al., Cancer Immunol. Immunother., 32:180-190 (1990)) and also because of potential allergic reactions (see, e.g., LoBuglio et al., Hybridoma, 5:5117-5123 (1986)).

[0107] Chimeric antibodies can be produced by recombinant DNA techniques known in the art (see Robinson et al., International Patent Publication PCT / US86 / 02269; Akira, et al., European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al., European Patent Application 173,494; Neuberger et al., International Application WO 86 / 01533; Cabilly et al. U.S. Patent No. 4,816,567; Cabilly et al., European Patent Application 125,023; Better et al. (1988 Science 240: 1041-1043); Liu et al. (1987) PNAS 84:3439-3443; Liu et al., 1987, J. Immunol. 139:3521-3526; Sun et al. (1987) PNAS 84:214-218; Nishimura et al., 1987, Cane. Res. 47:999-1005; Wood et al. (1985) Nature 314:446-449; and Shaw et al., 1988, J. Natl Cancer Inst. 80: 1553-1559).

[0108] A humanized or CDR-grafted antibody will have at least one or two but generally all three recipient CDRs (of heavy and or light immuoglobulin chains) replaced with a donor CDR. The antibody may be replaced with at least a portion of a non-human CDR or only some of the CDRs may be replaced with non-human CDRs. It is only necessary to replace the number of CDRs required for binding to the antigen. Preferably, the donor will be a rodent antibody, e.g., a rat or mouse antibody, and the recipient will be a human framework or a human consensus framework. Typically, the immunoglobulin providing the CDRs is called the “donor” and the immunoglobulin providing the framework is called the “acceptor.” In some embodiments, the donor immunoglobulin is a non-human (e.g., rodent). The acceptor framework is a naturally-occurring-62-P93296.WO01 Final specification 19.12.2025(e.g., a human) framework or a consensus framework, or a sequence about 85% or higher, preferably 90%, 95%, 99% or higher identical thereto.

[0109] As used herein, the term “consensus sequence” refers to the sequence formed from the most frequently occurring amino acids (or nucleotides) in a family of related sequences (See e.g., Winnaker, From Genes to Clones (Verlagsgesellschaft, Weinheim, Germany 1987). In a family of proteins, each position in the consensus sequence is occupied by the amino acid occurring most frequently at that position in the family. If two amino acids occur equally frequently, either can be included in the consensus sequence. A “consensus framework” refers to the framework region in the consensus immunoglobulin sequence.

[0110] An antibody molecule can be humanized by methods known in the art (see e.g., Morrison, S. L., 1985, Science 229: 1202-1207, by Oi et al., 1986, BioTechniques 4:214, and by Queen et al. US 5,585,089, US 5,693,761 and US 5,693,762, the contents of all of which are hereby incorporated by reference).

[0111] Humanized or CDR-grafted antibody molecules can be produced by CDR-grafting or CDR substitution, wherein one, two, or all CDRs of an immunoglobulin chain can be replaced. See e.g., U.S. Patent 5,225,539; Jones et al. 1986 Nature 321:552-525; Verhoeyan et al. 1988 Science 239:1534; Beidler et al. 1988 J. Immunol. 141:4053-4060; Winter US 5,225,539, the contents of all of which are hereby expressly incorporated by reference. Winter describes a CDR-grafting method which may be used to prepare the humanized antibodies of the present invention (UK Patent Application GB 2188638A, filed on March 26, 1987; Winter US 5,225,539), the contents of which is expressly incorporated by reference.

[0112] Also within the scope of the invention are humanized antibody molecules in which specific amino acids have been substituted, deleted or added. Criteria for selecting amino acids from the donor are described in US 5,585,089, e.g., columns 12-16 of US 5,585,089, e.g., columns 12-16 of US 5,585,089, the contents of which are hereby incorporated by reference. Other techniques for humanizing antibodies are described in Padlan et al. EP 519596 Al, published on December 23, 1992.

[0113] The antibody molecule can be a single chain antibody. A single-chain antibody (scFV) may be engineered (see, for example, Colcher, D. et al. (1999) Ann N Y Acad Sci 880:263-80; and Reiter, Y. (1996) Clin Cancer Res 2:245-52). The single chain antibody can be dimerized or multimerized to generate multivalent antibodies having specificities for different epitopes of the same target protein.-63-P93296.WO01 Final specification 19.12.2025

[0114] In yet other embodiments, the antibody molecule has a heavy chain constant region chosen from, e.g., the heavy chain constant regions of IgGl, IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgD, and IgE; particularly, chosen from, e.g., the (e.g., human) heavy chain constant regions of IgGl, IgG2, IgG3, and IgG4. In another embodiment, the antibody molecule has a light chain constant region chosen from, e.g., the (e.g., human) light chain constant regions of kappa or lambda. The constant region can be altered, e.g., mutated, to modify the properties of the antibody (e.g., to increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, and / or complement function). In some embodiments the antibody has: effector function; and can fix complement. In other embodiments the antibody does not; recruit effector cells; or fix complement. In another embodiment, the antibody has reduced or no ability to bind an Fc receptor. For example, it is a isotype or subtype, fragment or other mutant, which does not support binding to an Fc receptor, e.g., it has a mutagenized or deleted Fc receptor binding region.

[0115] In some embodiments, the immunoglobulin chain constant region (e.g., the Fc region) is altered, e.g., mutated, to increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, or complement function.

[0116] In other embodiments, an interface of a first and second immunoglobulin chain constant regions (e.g., a first and a second Fc region) is altered, e.g., mutated, to increase or decrease dimerization, e.g., relative to a non-engineered interface, e.g., a naturally-occurring interface. For example, dimerization of the immunoglobulin chain constant region (e.g., the Fc region) can be enhanced by providing an Fc interface of a first and a second Fc region with one or more of: a paired protuberance-cavity (“knob-in-a hole”), an electrostatic interaction, or a strand-exchange, such that a greater ratio of heteromultimer to homomultimer forms, e.g., relative to a nonengineered interface.

[0117] In some embodiments, the antibody molecules include a paired amino acid substitution at a position chosen from one or more of 347, 349, 350, 351, 366, 368, 370, 392, 394, 395, 397, 398, 399, 405, 407, or 409, e.g., of the Fc region of human IgGl For example, the immunoglobulin chain constant region (e.g., Fc region) can include a paired an amino acid substitution chosen from: T366S, E368A, or Y407V (e.g., corresponding to a cavity or hole), and T366W (e.g., corresponding to a protuberance or knob).

[0118] In other embodiments, the antibody molecule includes a half-life extender, e.g., a human serum albumin or an antibody molecule to human serum albumin.-64-P93296.WO01 Final specification 19.12.2025

[0119] Methods for altering an antibody constant region are known in the art. Antibodies with altered function, e.g. altered affinity for an effector ligand, such as FcR on a cell, or the Cl component of complement can be produced by replacing at least one amino acid residue in the constant portion of the antibody with a different residue (see e.g., EP 388,151 Al, U.S. Pat. No. 5,624,821 and U.S. Pat. No. 5,648,260, the contents of all of which are hereby incorporated by reference). Similar type of alterations could be described which if applied to the murine, or other species immunoglobulin would reduce or eliminate these functions.

[0120] An antibody molecule can be derivatized or linked to another functional molecule (e.g., another peptide or protein). As used herein, a “derivatized” antibody molecule is one that has been modified. Methods of derivatization include but are not limited to the addition of a fluorescent moiety, a radionucleotide, a toxin, an enzyme or an affinity ligand such as biotin. Accordingly, the antibody molecules of the invention are intended to include derivatized and otherwise modified forms of the antibodies described herein, including immunoadhesion molecules. For example, an antibody molecule can be functionally linked (by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities, such as another antibody (e.g., a bispecific antibody or a diabody), a detectable agent, a cytotoxic agent, a pharmaceutical agent, and / or a protein or peptide that can mediate association of the antibody or antibody portion with another molecule (such as a streptavidin core region or a polyhistidine tag).

[0121] One type of derivatized antibody molecule is produced by crosslinking two or more antibodies (of the same type or of different types, e.g., to create bispecific antibodies). Suitable crosslinkers include those that are heterobifunctional, having two distinctly reactive groups separated by an appropriate spacer (e.g., m-maleimidobenzoyl-N-hydroxysuccinimide ester) or homobifunctional (e.g., disuccinimidyl suberate). Such linkers are available from Pierce Chemical Company, Rockford, Ill.

[0122] In some embodiments, the anti-CD3 antibody molecule comprises at least one antigenbinding region, e.g., a variable region or an antigen-binding fragment thereof, from an antibody described herein, e.g., an antibody described in Tables 1-4 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences).

[0123] In some embodiments, the anti-CD3 antibody molecule comprises at least one, two, three or four variable regions from an antibody described herein, e.g., an antibody described in Tables-65-P93296.WO01 Final specification 19.12.20251-4 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99%, or 100%) to any of the aforesaid sequences.

[0124] In some embodiments, the anti-CD3 antibody molecule comprises at least one or two heavy chain variable regions from an antibody described herein, e.g., an antibody described in Tables 1- 4 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% or 100%) to any of the aforesaid sequences.

[0125] In some embodiments, the anti-CD3 antibody molecule comprises at least one or two heavy chain variable regions from an antibody described herein, e.g., an antibody described in Tables 1- 4 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99%, or 100%) to any of the aforesaid sequences.

[0126] In some embodiments, the anti-CD3 antibody molecule comprises a heavy chain constant region for an IgG4, e.g., a human IgG4. In still another embodiment, the anti-CD3 antibody molecule includes a heavy chain constant region for an IgGl, e.g., a human IgGl. In some embodiments, the heavy chain constant region comprises an amino sequence set forth in Table 2, or a sequence substantially (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99%, or 100%) thereto.

[0127] In some embodiments, the anti-CD3 antibody molecule comprises a lambda light chain constant region, e.g., a human lambda light chain constant region. In some embodiments, the light chain constant region comprises an amino sequence set forth in Table 5, or a sequence substantially (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99%, or 100%) thereto.

[0128] In some embodiments, the anti-CD3 antibody molecule includes at least one, two, or three complementarity determining regions (CDRs) from a heavy chain variable region (VH) of an antibody described herein, e.g., an antibody described in Table 3 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% or 100%) to any of the aforesaid sequences.

[0129] In some embodiments, the anti-CD3 antibody molecule, includes at least one, two, or three CDRs (or collectively all of the CDRs) from a heavy chain variable region comprising an amino acid sequence shown in Table 1. In some embodiments, one or more of the CDRs (or collectively all of the CDRs) have one, two, three, four, five, six or more changes, e.g., amino acid substitutions or deletions, relative to the amino acid sequence shown in Table 1.

[0130] In some embodiments, the anti-CD3 antibody molecule includes at least one, two, or three complementarity determining regions (CDRs) from a light chain variable region of an antibody -66-P93296.WO01 Final specification 19.12.2025described herein, e.g., an antibody chosen from an antibody described in Table 1 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences.

[0131] In some embodiments, the anti-CD3 antibody molecule includes at least one, two, or three CDRs (or collectively all of the CDRs) from a light chain variable region comprising an amino acid sequence shown in Table 1. In some embodiments, one or more of the CDRs (or collectively all of the CDRs) have one, two, three, four, five, six or more changes, e.g., amino acid substitutions or deletions, relative to the amino acid sequence shown in Table 1.

[0132] In some embodiments, the anti-CD3 antibody molecule includes at least one, two, three, four, five or six CDRs (or collectively all of the CDRs) from a heavy and light chain variable region comprising an amino acid sequence shown in Table 1. In some embodiments, one or more of the CDRs (or collectively all of the CDRs) have one, two, three, four, five, six or more changes, e.g., amino acid substitutions or deletions, relative to the amino acid sequence shown in Table 1.

[0133] In some embodiments, the anti-CD3 antibody molecule includes all six CDRs from an antibody described herein, e.g., an antibody described in Table 1, or closely related CDRs, e.g., CDRs which are identical or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions). In some embodiments, the anti-CD3 antibody molecule may include any CDR described herein.

[0134] In some embodiments, the anti-CD3 antibody molecule includes at least one, two, or three CDRs according to Kabat et al. (e.g., at least one, two, or three CDRs according to the Kabat definition as set out in Table 1) from a heavy chain variable region of an antibody described herein, e.g., an antibody described in Table 2 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% or 100%) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to one, two, or three CDRs according to Kabat et al. shown in Tables 1-5 and 7-8.

[0135] In some embodiments, the anti-CD3 antibody molecule includes at least one, two, or three CDRs according to Kabat et al. (e.g., at least one, two, or three CDRs according to the Kabat definition as set out in Table 2) from a light chain variable region of an antibody described herein, e.g., an antibody described in Table 2 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% or 100%) to any of the aforesaid sequences; or which have at -67-P93296.WO01 Final specification 19.12.2025least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to one, two, or three CDRs according to Kabat et al. shown in Tables 1-5 and 7-8.

[0136] In some embodiments, the anti-CD3 antibody molecule includes at least one, two, three, four, five, or six CDRs according to Kabat et al. (e.g., at least one, two, three, four, five, or six CDRs according to the Kabat definition as set out in Tables 1-5 and 7) from the heavy and light chain variable regions of an antibody described herein, e.g., an antibody described in Table 2; or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% or 100%) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to one, two, three, four, five, or six CDRs according to Kabat et al. shown in Tables 1-5 and 7-8.

[0137] In some embodiments, the anti-CD3 antibody molecule includes all six CDRs according to Kabat et al. (e.g., all six CDRs according to the Kabat definition as set out in Tables 1-5 and 7) from the heavy and light chain variable regions of an antibody described herein, e.g., an antibody described in Tables 1-5 and 7 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% or 100%) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to all six CDRs according to Kabat et al. shown in Tables 1-5 and 7-8.

[0138] In some embodiments, the anti-CD3 antibody molecule includes at least one, two, or three hypervariable loops that have the same canonical structures as the corresponding hypervariable loop of an antibody described herein, e.g., an antibody described in Table 2, e.g., the same canonical structures as at least loop 1 and / or loop 2 of the heavy and / or light chain variable domains of an antibody described herein. See, e.g., Chothia et al., (1992) J. Mol. Biol. 227:799- 817; Tomlinson et al., (1992) J. Mol. Biol. 227:776-798 for descriptions of hypervariable loop canonical structures. These structures can be determined by inspection of the tables described in these references.

[0139] In some embodiments, the anti-CD3 antibody molecule includes at least one, two, or three CDRs according to Chothia et al. or IMGT (e.g., at least one, two, or three CDRs according to the Chothia or IMGT definition as set out in Tables 1 A and IB) from a heavy chain variable region of an antibody described herein, e.g., an antibody described in Table 3 or a sequence substantially -68-P93296.WO01 Final specification 19.12.2025identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% or 100%) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to one, two, or three CDRs according to Chothia et al or IM GT. shown in Tables 1A and IB.

[0140] In some embodiments, the anti-CD3 antibody molecule includes at least one, two, or three CDRs according to Chothia et al. or IMGT (e.g., at least one, two, or three CDRs according to the Chothia or IMGT definition as set out in Tables 1A and IB) from a light chain variable region of an antibody described herein, e.g., an antibody described in Table 4 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% or 100%) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to one, two, or three CDRs according to Chothia et al or IMGT. shown in Tables 1A and IB.

[0141] In some embodiments, the anti-CD3 antibody molecule includes at least one, two, three, four, five, or six CDRs according to Chothia et al. or IMGT (e.g., at least one, two, three, four, five, or six CDRs according to the Chothia or IMGT definition as set out in Tables 1A and IB) from the heavy and light chain variable regions of an antibody described herein, e.g., an antibody described in Tables 3 and 4; or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% or 100%) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to one, two, three, four, five, or six CDRs according to Chothia et al or IMGT shown in Tables 1A and IB.

[0142] In some embodiments, the anti-CD3 antibody molecule includes all six CDRs according to Chothia et al. or IMGT (e.g., all six CDRs according to the Chothia or IMGT definition as set out in Tables 1A and IB) from the heavy and light chain variable regions of an antibody described herein, e.g., an antibody described in Tables 1-5 and 7-8 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% or 100%) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to all six CDRs according to Chothia et al or IMGT as shown in Tables 1A and IB..-69-P93296.WO01 Final specification 19.12.2025

[0143] In some embodiments, the anti-CD3 antibody molecule includes a combination of CDRs or hypervariable loops defined according to Kabat et al., Chothia et al., IMGT, or as described in Tables 1-5 and 7-8.

[0144] In some embodiments, the anti-CD3 antibody molecule can contain any combination of CDRs or hypervariable loops according to the Kabat, Chothia or IMGT definitions.

[0145] In some embodiments, a combined CDR as set out in Tables 1-5 and 7-8 is a CDR that comprises a Kabat CDR, a Chothia CDR, and an IMGT CDR.

[0146] In some embodiments, the anti-CD3 antibody molecule includes a combination of CDRs or hypervariable loops identified as combined CDRs in Tables 1-5 and 7-8. In some embodiments, the anti-CD3 antibody molecule can contain any combination of CDRs or hypervariable loops according the “combined” CDRs are described in Tables 1-5 and 7-8.

[0147] In some embodiments, e.g., an embodiment comprising a variable region, a CDR (e.g., a combined CDR, Chothia CDR or Kabat CDR), or other sequence referred to herein, e.g., in Table 2, the antibody molecule is a monospecific antibody molecule, a bispecific antibody molecule, a bivalent antibody molecule, a biparatopic antibody molecule, or an antibody molecule that comprises an antigen binding fragment of an antibody, e.g., a half antibody or antigen binding fragment of a half antibody.

[0148] In some embodiments, the anti-CD3 antibody molecule comprises at least one or two light chain variable regions from an antibody described herein, e.g., an antibody described in Tables 1- 5 and 7-8 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99%, or 100%) to any of the aforesaid sequences.

[0149] In some embodiments, the anti-CD3 antibody molecule described herein comprises a VH and a VL. In some embodiments, the VH comprises a heavy chain complementarity determining region 1 (HCDR1) amino acid sequence of any one of SEQ ID NOs: 1-4, a heavy chain complementarity determining region 2 (HCDR2) amino acid sequence of any one of SEQ ID NOs: 5-12, and a heavy chain complementarity determining region 3 (HCDR3) amino acid sequence of SEQ ID NO: 13 or SEQ ID NO: 14.

[0150] In some embodiments, the VL comprises a light chain complementarity determining region 1 (LCDR1) amino acid sequence of any one of SEQ ID NOs: 15-19 and 95, a light chain complementarity determining region 2 (LCDR2) amino acid sequence of any one of SEQ ID NOs: 20-26, and a light chain complementarity determining region 3 (LCDR3) amino acid sequence of any one of SEQ ID NOs: 27-29.-70-P93296.WO01 Final specification 19.12.2025

[0151] In some embodiments, the VL comprises a light chain complementarity determining region 1 (LCDR1) amino acid sequence of any one of SEQ ID NOs: 15-19 , SEQ ID NO: 95, or SEQ ID NOs: 130-132, a light chain complementarity determining region 2 (LCDR2) amino acid sequence of any one of SEQ ID NOs: 20-26 or SEQ ID NO: 194, and a light chain complementarity determining region 3 (LCDR3) amino acid sequence of any one of SEQ ID NOs: 27-29.

[0152] In some embodiments, the molecule is: a. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29; b. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; c. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; d. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 23, and a LCDR3 amino acid sequence of SEQ ID NO: 27; e. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; f. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; g. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and-71-P93296.WO01 Final specification 19.12.2025the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 24, and a LCDR3 amino acid sequence of SEQ ID NO: 27; h. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; i. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 28; j. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 19, a LCDR2 amino acid sequence of SEQ ID NO: 25, and a LCDR3 amino acid sequence of SEQ ID NO: 27; k. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 29; l. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 10, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 28; m. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 12, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 24, and a LCDR3 amino acid sequence of SEQ ID NO: 27; n. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 4, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; o. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and-72-P93296.WO01 Final specification 19.12.2025the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; p. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27; q. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 19, a LCDR2 amino acid sequence of SEQ ID NO: 25, and a LCDR3 amino acid sequence of SEQ ID NO: 27; r. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 5, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 26, and a LCDR3 amino acid sequence of SEQ ID NO: 27; s. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29; t. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29; u. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 24, and a LCDR3 amino acid sequence of SEQ ID NO: 29; v. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 9, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29; w. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 3, a HCDR2 amino acid sequence of SEQ ID NO: 11, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and-73-P93296.WO01 Final specification 19.12.2025the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 29; x. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29; y. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29; z. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29; aa. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; bb. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 5, and a HCDR3 amino acid sequence of SEQ ID NO: 13; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 15, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or cc. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 13; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 95, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0153] In some embodiments, the molecule is: a. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29;-74-P93296.WO01 Final specification 19.12.2025b. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; c. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; d. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 23, and a LCDR3 amino acid sequence of SEQ ID NO: 27; e. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; f. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; g. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 24, and a LCDR3 amino acid sequence of SEQ ID NO: 27; h. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; i. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 28;-75-P93296.WO01 Final specification 19.12.2025j. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 19, a LCDR2 amino acid sequence of SEQ ID NO: 25, and a LCDR3 amino acid sequence of SEQ ID NO: 27; k. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 29; l. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 10, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 28; m. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 12, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 24, and a LCDR3 amino acid sequence of SEQ ID NO: 27; n. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 4, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; o. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; p. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27; q. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 19, a LCDR2 amino acid sequence of SEQ ID NO: 25, and a LCDR3 amino acid sequence of SEQ ID NO: 27;-76-P93296.WO01 Final specification 19.12.2025r. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 5, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 26, and a LCDR3 amino acid sequence of SEQ ID NO: 27; s. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29; t. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29; u. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 24, and a LCDR3 amino acid sequence of SEQ ID NO: 29; v. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 9, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29; w. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 3, a HCDR2 amino acid sequence of SEQ ID NO: 11, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 29; x. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29; y. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29;-77-P93296.WO01 Final specification 19.12.2025z. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29; aa. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; bb. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 5, and a HCDR3 amino acid sequence of SEQ ID NO: 13; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 15, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or cc. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 13; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 95, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27; dd. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 13; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or ee. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 95, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or ff. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or gg. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 13; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 95, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or-78-P93296.WO01 Final specification 19.12.2025hh. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 130, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or ii. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 131, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or jj. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 130, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or kk. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 131, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or11. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 132, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or mm. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or nn. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and-79-P93296.WO01 Final specification 19.12.2025the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or oo. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 132, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or pp. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 130, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or qq. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 131, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or rr. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or ss. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or tt. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 131, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or uu. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and-80-P93296.WO01 Final specification 19.12.2025the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 130, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or vv. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or ww. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or xx. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or yy. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7 and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 131, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or zz. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 130, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or aaa. the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27.-81-P93296.WO01 Final specification 19.12.2025

[0154] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29.

[0155] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0156] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0157] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 23, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0158] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27. In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27. In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 24, and a LCDR3 amino acid sequence of SEQ ID NO: 27.In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27.-82-P93296.WO01 Final specification 19.12.2025In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 28.In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 19, a LCDR2 amino acid sequence of SEQ ID NO: 25, and a LCDR3 amino acid sequence of SEQ ID NO: 27.In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 29.In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 10, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 28.In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 12, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 24, and a LCDR3 amino acid sequence of SEQ ID NO: 27.In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 4, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27.In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27.In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27.-83-P93296.WO01 Final specification 19.12.2025In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 19, a LCDR2 amino acid sequence of SEQ ID NO: 25, and a LCDR3 amino acid sequence of SEQ ID NO: 27.In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 5, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 26, and a LCDR3 amino acid sequence of SEQ ID NO: 27.In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29.In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29.In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 24, and a LCDR3 amino acid sequence of SEQ ID NO: 29.In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 9, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29.In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 3, a HCDR2 amino acid sequence of SEQ ID NO: 11, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 29.In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29.-84-P93296.WO01 Final specification 19.12.2025In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29.In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29.In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27.In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 5, and a HCDR3 amino acid sequence of SEQ ID NO: 13; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 15, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0159] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 13; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 95, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27. In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 13; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0160] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 13; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0161] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 95, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27.-85-P93296.WO01 Final specification 19.12.2025

[0162] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0163] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 13; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 95, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0164] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 130, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 131, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0165] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 130, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0166] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 131, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0167] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 132, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0168] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27.-86-P93296.WO01 Final specification 19.12.2025

[0169] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0170] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 132, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0171] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 130, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 131, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0172] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0173] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0174] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 131, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0175] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ -87-P93296.WO01 Final specification 19.12.2025ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 130, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0176] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0177] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0178] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27. In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7 and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 131, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0179] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 130, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

[0180] In some embodiments, the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27.-88-P93296.WO01 Final specification 19.12.2025

[0181] In some embodiments, the VH further comprises:(a) a heavy chain framework region 1 (HFWR1) amino acid sequence of SEQ ID NO: 30 or SEQ ID NO: 31;(b) a heavy chain framework region 2 (HFWR2) amino acid sequence of any one of SEQ ID NOs: 32-35;(c) a heavy chain framework region 3 (HFWR3) amino acid sequence of any one of SEQ ID NOs: 36-45; and(d) a heavy chain framework region 4 (HFWR4) amino acid sequence of SEQ ID NO: 46.

[0182] In some embodiments, the VL further comprises:(e) a light chain framework region 1 (LFWR1) amino acid sequence of SEQ ID NO: 47;(f) a light chain framework region 2 (LFWR2) amino acid sequence of any one of SEQ ID NOs: 48-50 or SEQ ID NOs: 215-218;(g) a light chain framework region 3 (LFWR3) amino acid sequence of any one of SEQ ID NOs: 51-54; and(h) a light chain framework region 4 (LFWR4) amino acid sequence of SEQ ID NO: 55.

[0183] In some embodiments, the VH further comprises a heavy chain framework region 1 (HFWR1) amino acid sequence of SEQ ID NO: 30 or SEQ ID NO: 31.In some embodiments, the VH further comprises a heavy chain framework region 2 (HFWR2) amino acid sequence of any one of SEQ ID NOs: 32-35.In some embodiments, the VH further comprises a heavy chain framework region 3 (HFWR3) amino acid sequence of any one of SEQ ID NOs: 36-45.In some embodiments, the VH further comprises a heavy chain framework region 4 (HFWR4) amino acid sequence of SEQ ID NO: 46.In some embodiments, the VL further comprises a light chain framework region 1 (LFWR1) amino acid sequence of SEQ ID NO: 47.In some embodiments, the VH further comprises a light chain framework region 2 (LFWR2) amino acid sequence of any one of SEQ ID NOs: 48-50 or SEQ ID NOs: 215-218.In some embodiments, the VH further comprises a light chain framework region 3 (LFWR3) amino acid sequence of any one of SEQ ID NOs: 51-54.In some embodiments, the VH further comprises a light chain framework region 4 (LFWR4) amino acid sequence of SEQ ID NO: 55.-89-P93296.WO01 Final specification 19.12.2025

[0184] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of any one of SEQ ID NOs: 56- 72. In some embodiments, the VL comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of any one of SEQ ID NOs: 73- 90.

[0185] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of any one of SEQ ID NOs: 56- 72 and the VL comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of any one of SEQ ID NOs: 73-90.

[0186] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of any one of SEQ ID NOs: 56- 72, or SEQ ID NO: 181. In some embodiments, the VL comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of any one of SEQ ID NOs: 73-90, SEQ ID NOs: 133-180, or SEQ ID NOs: 182-193.

[0187] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of any one of SEQ ID NOs: 56- 72, or SEQ ID NO: 181, and the VL comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at -90-P93296.WO01 Final specification 19.12.2025least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of any one of SEQ ID NOs: 73- 90, SEQ ID NOs: 133-180, or SEQ ID NOs: 182-193.

[0188] In some embodiments, the VH comprises the sequence of any one of SEQ ID NOs: 56- 72, or SEQ ID NO: 181. In some embodiments, the VL comprises the sequence of any one of SEQ ID NOs: 73-90, SEQ ID NOs: 133-180, or SEQ ID NOs 182-193.

[0189] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 77.

[0190] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 76.

[0191] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 84.

[0192] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at -91-P93296.WO01 Final specification 19.12.2025least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 78.

[0193] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 86.

[0194] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 76.

[0195] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 80.

[0196] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at -92-P93296.WO01 Final specification 19.12.2025least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 79.

[0197] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 75.

[0198] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 82.

[0199] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 83.

[0200] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at -93-P93296.WO01 Final specification 19.12.2025least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 66 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 75.

[0201] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 72 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 80.

[0202] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 71 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 87.

[0203] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 61 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 76.

[0204] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at -94-P93296.WO01 Final specification 19.12.2025least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 61 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 81.

[0205] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 61 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 82.

[0206] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 60 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 85.

[0207] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 62 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 77.

[0208] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at -95-P93296.WO01 Final specification 19.12.2025least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 63 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 77.

[0209] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 62 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 90.

[0210] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 64 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 77.

[0211] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 83.

[0212] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at -96-P93296.WO01 Final specification 19.12.2025least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 68 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 89.

[0213] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 91 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 77.

[0214] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 70 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 77.

[0215] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 65 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 88.

[0216] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at -97-P93296.WO01 Final specification 19.12.2025least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 56 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 73. or

[0217] In some embodiments, the VH comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 57 and the VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 74.

[0218] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 157.

[0219] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 157.

[0220] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 84.

[0221] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 57 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 74.

[0222] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ -98-P93296.WO01 Final specification 19.12.2025ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 133.

[0223] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 134.

[0224] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 135.

[0225] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 136.

[0226] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 137.

[0227] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 216.

[0228] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 138.

[0229] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 139.

[0230] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ -99-P93296.WO01 Final specification 19.12.2025ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 140.

[0231] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 141.

[0232] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 142.

[0233] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 143.

[0234] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 76.

[0235] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 76.

[0236] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 140.

[0237] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 141.

[0238] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ -100-P93296.WO01 Final specification 19.12.2025ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 142.

[0239] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 143.

[0240] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 182.

[0241] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 183.

[0242] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 184.

[0243] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 185.

[0244] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 186.

[0245] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 187.

[0246] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ -101-P93296.WO01 Final specification 19.12.2025ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 188.

[0247] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 189.

[0248] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 190.

[0249] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 191.

[0250] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 192.

[0251] In some embodiments, the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 193.

[0252] In some embodiments,(a) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 77;(b) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 76;(c) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 84;(d) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 78;-102-P93296.WO01 Final specification 19.12.2025(e) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 86;(f) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 76;(g) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 80;(h) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 79;(i) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence ofSEQ ID NO: 75;(j) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence ofSEQ ID NO: 82;(k) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 83;(l) the VH comprises the sequence of SEQ ID NO: 66 and the VL comprises the sequence ofSEQ ID NO: 75;(m) the VH comprises the sequence of SEQ ID NO: 72 and the VL comprises the sequence of SEQ ID NO: 80;(n) the VH comprises the sequence of SEQ ID NO: 71 and the VL comprises the sequence of SEQ ID NO: 87;(o) the VH comprises the sequence of SEQ ID NO: 61 and the VL comprises the sequence of SEQ ID NO: 76;(p) the VH comprises the sequence of SEQ ID NO: 61 and the VL comprises the sequence of SEQ ID NO: 81;(q) the VH comprises the sequence of SEQ ID NO: 61 and the VL comprises the sequence of SEQ ID NO: 82;(r) the VH comprises the sequence of SEQ ID NO: 60 and the VL comprises the sequence of SEQ ID NO: 85;(s) the VH comprises the sequence of SEQ ID NO: 62 and the VL comprises the sequence of SEQ ID NO: 77;(t) the VH comprises the sequence of SEQ ID NO: 63 and the VL comprises the sequence ofSEQ ID NO: 77;-103-P93296.WO01 Final specification 19.12.2025(u) the VH comprises the sequence of SEQ ID NO: 62 and the VL comprises the sequence of SEQ ID NO: 90;(v) the VH comprises the sequence of SEQ ID NO: 64 and the VL comprises the sequence of SEQ ID NO: 77;(w) the VH comprises the sequence of SEQ ID NO: 67 and the VL comprises the sequence of SEQ ID NO: 83;(x) the VH comprises the sequence of SEQ ID NO: 68 and the VL comprises the sequence of SEQ ID NO: 89;(y) the VH comprises the sequence of SEQ ID NO: 91 and the VL comprises the sequence of SEQ ID NO: 77;(z) the VH comprises the sequence of SEQ ID NO: 70 and the VL comprises the sequence of SEQ ID NO: 77;(aa) the VH comprises the sequence of SEQ ID NO: 65 and the VL comprises the sequence of SEQ ID NO: 88;(bb) the VH comprises the sequence of SEQ ID NO: 57 and the VL comprises the sequence of SEQ ID NO: 84; or(cc) the VH comprises the sequence of SEQ ID NO: 57 and the VL comprises the sequence of SEQ ID NO: 157; or(dd) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 74; or(ee) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 157; or(ff) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 84; or(gg) the VH comprises the sequence of SEQ ID NO: 57 and the VL comprises the sequence of SEQ ID NO: 74; or(hh) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 133; or(ii) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 134; or(jj) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 135; or-104-P93296.WO01 Final specification 19.12.2025(kk) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 136; or(11) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 137; or(mm) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 216; or(nn) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 138; or(oo) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 139; or(pp) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 140; or(qq) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 141; or(rr) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 142; or(ss) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 143; or(tt) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 76; or(uu) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 76; or(vv) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 140; or(ww) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 141; or(xx) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 142; or(yy) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 143; or(zz) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence ofSEQ ID NO: 182; or-105-P93296.WO01 Final specification 19.12.2025(aaa) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 183; or(bbb) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 184; or(ccc) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 185; or(ddd) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 186; or(eee) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 187; or(fff) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 188; or(ggg) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 189; or(hhh) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 190; or(iii) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 191; or(jjj ) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 192; or(kkk) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 193.

[0253] In some embodiments, the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 77. In some embodiments, the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 76. In some embodiments, the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 84. In some embodiments, the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 78. In some embodiments, the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 86. In some embodiments, the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 76. In some embodiments, the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 80. In some-106-P93296.WO01 Final specification 19.12.2025embodiments, the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 79. In some embodiments, the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 75. In some embodiments, the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 82. In some embodiments, the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 83. In some embodiments, the VH comprises the sequence of SEQ ID NO: 66 and the VL comprises the sequence of SEQ ID NO: 75. In some embodiments, the VH comprises the sequence of SEQ ID NO: 72 and the VL comprises the sequence of SEQ ID NO: 80. In some embodiments, the VH comprises the sequence of SEQ ID NO: 71 and the VL comprises the sequence of SEQ ID NO: 87. In some embodiments, the VH comprises the sequence of SEQ ID NO: 61 and the VL comprises the sequence of SEQ ID NO:76. In some embodiments, the VH comprises the sequence of SEQ ID NO: 61 and the VL comprises the sequence of SEQ ID NO: 81. In some embodiments, the VH comprises the sequence of SEQ ID NO: 61 and the VL comprises the sequence of SEQ ID NO: 82. In some embodiments, the VH comprises the sequence of SEQ ID NO: 60 and the VL comprises the sequence of SEQ ID NO: 85. In some embodiments, the VH comprises the sequence of SEQ ID NO: 62 and the VL comprises the sequence of SEQ ID NO: 77. In some embodiments, the VH comprises the sequence of SEQ ID NO: 63 and the VL comprises the sequence of SEQ ID NO:77. In some embodiments, the VH comprises the sequence of SEQ ID NO: 62 and the VL comprises the sequence of SEQ ID NO: 90. In some embodiments, the VH comprises the sequence of SEQ ID NO: 64 and the VL comprises the sequence of SEQ ID NO: 77. In some embodiments, the VH comprises the sequence of SEQ ID NO: 67 and the VL comprises the sequence of SEQ ID NO: 83. In some embodiments, the VH comprises the sequence of SEQ ID NO: 68 and the VL comprises the sequence of SEQ ID NO: 89. In some embodiments, the VH comprises the sequence of SEQ ID NO: 91 and the VL comprises the sequence of SEQ ID NO: 77. In some embodiments, the VH comprises the sequence of SEQ ID NO: 70 and the VL comprises the sequence of SEQ ID NO: 77. In some embodiments, the VH comprises the sequence of SEQ ID NO: 65 and the VL comprises the sequence of SEQ ID NO: 88. In some embodiments, the VH comprises the sequence of SEQ ID NO: 57 and the VL comprises the sequence of SEQ ID NO: 84. In some embodiments, the VH comprises the sequence of SEQ ID NO: 57 and the VL comprises the sequence of SEQ ID NO: 157. In some embodiments, the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO:-107-P93296.WO01 Final specification 19.12.202574. In some embodiments, the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 157. In some embodiments, the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 84. In some embodiments, the VH comprises the sequence of SEQ ID NO: 57 and the VL comprises the sequence of SEQ ID NO: 74. In some embodiments, the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 133. In some embodiments, the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 134. In some embodiments, the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 135. In some embodiments, the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 136. In some embodiments, the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 137. In some embodiments, the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 216. In some embodiments, the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 138. In some embodiments, the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 139. In some embodiments, the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 140.

[0254] In some embodiments, the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 141. In some embodiments, the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 142. In some embodiments, the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 143. In some embodiments, the VH comprises the seque...

Claims

CLAIMSWHAT IS CLAIMED IS:

1. A molecule comprising an antigen binding domain that binds to CD3, wherein the molecule comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises:(a) a heavy chain complementarity determining region 1 (HCDR1) amino acid sequence of any one of SEQ ID NOs: 1-4,(b) a heavy chain complementarity determining region 2 (HCDR2) amino acid sequence of any one of SEQ ID NOs: 5-12, and(c) a heavy chain complementarity determining region 3 (HCDR3) amino acid sequence of SEQ ID NO: 13 or SEQ ID NO: 14.

2. The molecule of claim 1, wherein the VL comprises:(a) a light chain complementarity determining region 1 (LCDR1) amino acid sequence of any one of SEQ ID NOs: 15-19, SEQ ID NO: 95, or SEQ ID NOs: 130-132,(b) a light chain complementarity determining region 2 (LCDR2) amino acid sequence of any one of SEQ ID NOs: 20-26 or SEQ ID NO: 194, and(c) a light chain complementarity determining region 3 (LCDR3) amino acid sequence of any one of SEQ ID NOs: 27-29.

3. The molecule of claim 1 or 2, wherein:(a) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29;(b) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27;(c) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and-275-P93296.WO01 Final specification 19.12.2025the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27;(d) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 23, and a LCDR3 amino acid sequence of SEQ ID NO: 27;(e) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27;(f) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27;(g) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 24, and a LCDR3 amino acid sequence of SEQ ID NO: 27;(h) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27;(i) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and-276-P93296.WO01 Final specification 19.12.2025the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 28;(j) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 19, a LCDR2 amino acid sequence of SEQ ID NO: 25, and a LCDR3 amino acid sequence of SEQ ID NO: 27;(k) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 29;(l) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 10, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 28;(m) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 12, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 24, and a LCDR3 amino acid sequence of SEQ ID NO: 27;(n) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 4, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27;(o) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and-277-P93296.WO01 Final specification 19.12.2025the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27;(p) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27;(q) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 19, a LCDR2 amino acid sequence of SEQ ID NO: 25, and a LCDR3 amino acid sequence of SEQ ID NO: 27;(r) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 5, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 26, and a LCDR3 amino acid sequence of SEQ ID NO: 27;(s) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29;(t) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29;(u) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and-278-P93296.WO01 Final specification 19.12.2025the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 24, and a LCDR3 amino acid sequence of SEQ ID NO: 29;(v) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 9, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29;(w) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 3, a HCDR2 amino acid sequence of SEQ ID NO: 11, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 29;(x) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29;(y) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29;(z) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 2, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 29;(aa) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and-279-P93296.WO01 Final specification 19.12.2025the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27;(bb) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 5, and a HCDR3 amino acid sequence of SEQ ID NO: 13; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 15, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(cc) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 13; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 95, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(dd) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 13; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(ee) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 95, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(ff) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(gg) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 8, and a HCDR3 amino acid sequence of SEQ ID NO: 13; and-280-P93296.WO01 Final specification 19.12.2025the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 95, a LCDR2 amino acid sequence of SEQ ID NO: 20, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(hh) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 130, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(ii) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 131, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(jj ) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 130, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(kk) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 131, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(11) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 132, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(mm) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and-281-P93296.WO01 Final specification 19.12.2025the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(nn) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 16, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(oo) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 6, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 132, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(pp) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 130, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(qq) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 131, a LCDR2 amino acid sequence of SEQ ID NO: 21, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(rr) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(ss) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and-282-P93296.WO01 Final specification 19.12.2025the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(tt) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 131, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(uu) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 130, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(vv) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(ww) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 17, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(xx) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 22, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(yy) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7 and a HCDR3 amino acid sequence of SEQ ID NO: 14; and-283-P93296.WO01 Final specification 19.12.2025the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 131, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(zz) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 130, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27; or(aaa) the VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 7, and a HCDR3 amino acid sequence of SEQ ID NO: 14; and the VL comprises a LCDR1 amino acid sequence of SEQ ID NO: 18, a LCDR2 amino acid sequence of SEQ ID NO: 194, and a LCDR3 amino acid sequence of SEQ ID NO: 27.

4. The molecule of any one of claims 1-3, wherein the VH further comprises:(a) a heavy chain framework region 1 (HFWR1) amino acid sequence of SEQ ID NO: 30 or SEQ ID NO: 31;(b) a heavy chain framework region 2 (HFWR2) amino acid sequence of any one of SEQ ID NOs: 32-35;(c) a heavy chain framework region 3 (HFWR3) amino acid sequence of any one of SEQ ID NOs: 36-45; and(d) a heavy chain framework region 4 (HFWR4) amino acid sequence of SEQ ID NO: 46.

5. The molecule of any one of claims 1-4, wherein the VL further comprises:(a) a light chain framework region 1 (LFWR1) amino acid sequence of SEQ ID NO: 47;(b) a light chain framework region 2 (LFWR2) amino acid sequence of any one of SEQ ID NOs: 48-50 or SEQ ID NOs: 215-218;(c) a light chain framework region 3 (LFWR3) amino acid sequence of any one of SEQ ID NOs: 51-54; and(d) a light chain framework region 4 (LFWR4) amino acid sequence of SEQ ID NO: 55.

6. The molecule of any one of claims 1-5, wherein the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NOs: 56-72, or SEQ ID NO: 181.-284-P93296.WO01 Final specification 19.12.20257. The molecule of claim 6, wherein the VH comprises the sequence of any one of SEQ ID NOs: 56-72, or SEQ ID NO: 181.

8. The molecule of any one of claims 1-7, wherein the VL comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NOs: 73-90, SEQ ID NOs: 133-180, or SEQ ID NOs: 182-193.

9. The molecule of claim 8, wherein the VL comprises the sequence of any one of SEQ ID NOs: 73-90, SEQ ID NOs: 133-180, or SEQ ID NOs 182-193.

10. The molecule of any one of claims 1-9, wherein:(a) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 77;(b) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 76;(c) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 84;(d) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 78;(e) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 86;(f) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL-285-P93296.WO01 Final specification 19.12.2025comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 76;(g) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 80;(h) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 79;(i) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 75;(j) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 82;(k) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 83;(l) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 66 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 75;(m) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 72 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 80;(n) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 71 and the VL-286-P93296.WO01 Final specification 19.12.2025comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 87;(o) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 61 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 76;(p) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 61 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 81;(q) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 61 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 82;(r) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 60 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 85;(s) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 62 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 77;(t) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 63 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 77;(u) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 62 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 90;(v) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 64 and the VL-287-P93296.WO01 Final specification 19.12.2025comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 77;(w) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 67 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 83;(x) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 68 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 89;(y) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 91 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 77;(z) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 70 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 77;(aa) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 65 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 88;(bb) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 57 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 84; or(cc) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 57 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 74; or-288-P93296.WO01 Final specification 19.12.2025(dd) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 157; or(ee) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 157; or(ff) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 84; or(gg) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 57 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 74; or(hh) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 133; or(ii) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 134; or(jj) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 135; or(kk) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 136; or-289-P93296.WO01 Final specification 19.12.2025(11) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 137; or(mm) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 216; or(nn) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 138; or(oo) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 139; or(pp) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 140; or(qq) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 141; or(rr) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 142; or(ss) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 143; or-290-P93296.WO01 Final specification 19.12.2025(tt) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 76; or(uu) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 76; or(vv) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 140; or(ww) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 141; or(xx) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 142; or(yy) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 143; or(zz) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 182; or(aaa) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 183; or-291-P93296.WO01 Final specification 19.12.2025(bbb) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 184; or(ccc) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 185; or(ddd) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 186; or(eee) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 187; or(fff) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 188; or(ggg) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 189; or(hhh) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 190; or(iii) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 191 ; or-292-P93296.WO01 Final specification 19.12.2025(jjj ) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 192; or(kkk) the VH comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 59 and the VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 193.

11. The molecule of claim 10, wherein:(a) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 77;(b) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 76;(c) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 84;(d) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 78;(e) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 86;(f) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 76;(g) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 80;(h) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 79;(i) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 75;(j) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 82;(k) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 83;-293-P93296.WO01 Final specification 19.12.2025(l) the VH comprises the sequence of SEQ ID NO: 66 and the VL comprises the sequence of SEQ ID NO: 75;(m) the VH comprises the sequence of SEQ ID NO: 72 and the VL comprises the sequence of SEQ ID NO: 80;(n) the VH comprises the sequence of SEQ ID NO: 71 and the VL comprises the sequence of SEQ ID NO: 87;(o) the VH comprises the sequence of SEQ ID NO: 61 and the VL comprises the sequence of SEQ ID NO: 76;(p) the VH comprises the sequence of SEQ ID NO: 61 and the VL comprises the sequence of SEQ ID NO: 81;(q) the VH comprises the sequence of SEQ ID NO: 61 and the VL comprises the sequence of SEQ ID NO: 82;(r) the VH comprises the sequence of SEQ ID NO: 60 and the VL comprises the sequence of SEQ ID NO. 85;(s) the VH comprises the sequence of SEQ ID NO: 62 and the VL comprises the sequence of SEQ ID NO: 77;(t) the VH comprises the sequence of SEQ ID NO: 63 and the VL comprises the sequence ofSEQ ID NO: 77;(u) the VH comprises the sequence of SEQ ID NO: 62 and the VL comprises the sequence of SEQ ID NO: 90;(v) the VH comprises the sequence of SEQ ID NO: 64 and the VL comprises the sequence of SEQ ID NO: 77;(w) the VH comprises the sequence of SEQ ID NO: 67 and the VL comprises the sequence of SEQ ID NO: 83;(x) the VH comprises the sequence of SEQ ID NO: 68 and the VL comprises the sequence of SEQ ID NO: 89;(y) the VH comprises the sequence of SEQ ID NO: 91 and the VL comprises the sequence of SEQ ID NO: 77;(z) the VH comprises the sequence of SEQ ID NO: 70 and the VL comprises the sequence of SEQ ID NO: 77;(aa) the VH comprises the sequence of SEQ ID NO: 65 and the VL comprises the sequence of SEQ ID NO: 88;-294-P93296.WO01 Final specification 19.12.2025(bb) the VH comprises the sequence of SEQ ID NO: 57 and the VL comprises the sequence of SEQ ID NO: 84; or(cc) the VH comprises the sequence of SEQ ID NO: 57 and the VL comprises the sequence of SEQ ID NO: 157; or(dd) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 74; or(ee) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 157; or(ff) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 84; or(gg) the VH comprises the sequence of SEQ ID NO: 57 and the VL comprises the sequence of SEQ ID NO: 74; or(hh) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 133; or(ii) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 134; or(jj ) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 135; or(kk) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 136; or(11) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 137; or(mm) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 216; or(nn) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 138; or(oo) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 139; or(pp) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 140; or(qq) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 141; or-295-P93296.WO01 Final specification 19.12.2025(rr) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 142; or(ss) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 143; or(tt) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 76; or(uu) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 76; or(vv) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 140; or(ww) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 141; or(xx) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 142; or(yy) the VH comprises the sequence of SEQ ID NO: 58 and the VL comprises the sequence of SEQ ID NO: 143; or(zz) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 182; or(aaa) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 183; or(bbb) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 184; or(ccc) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 185; or(ddd) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 186; or(eee) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 187; or(fff) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 188; or(ggg) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 189; or-296-P93296.WO01 Final specification 19.12.2025(hhh) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 190; or(iii) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 191; or(jjj ) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 192; or(kkk) the VH comprises the sequence of SEQ ID NO: 59 and the VL comprises the sequence of SEQ ID NO: 193.

12. The molecule of any one of claims 1-11, wherein the antigen binding domain is a full antibody or antigen-binding fragment thereof, a bivalent antibody, bispecific antibody, or a biparatopic antibody.

13. The molecule of any one of claims 1-12, wherein the antigen binding domain is a Fab, F(ab’)2, Fv, a single chain Fv (scFv), a diabody, a single domain antibody, or a camelid antibody.

14. The molecule of any one of claims 1-13, wherein the antigen binding domain is a Fab or a scFv.

15. The molecule of any one of claims 1-14, wherein the antigen binding domain comprises one or more heavy chain constant regions selected from the group consisting of IgGl heavy chain constant region or functional fragment thereof, IgG2 heavy chain constant region or functional fragment thereof, IgG3 heavy chain constant region or functional fragment thereof, IgGAl heavy chain constant region or functional fragment thereof, IgGA2 heavy chain constant region or functional fragment thereof, IgG4 heavy chain constant region or functional fragment thereof, IgJ heavy chain constant region or functional fragment thereof, IgM heavy chain constant region or functional fragment thereof, IgD heavy chain constant region or functional fragment thereof, and IgE heavy chain constant region or functional fragment thereof.

16. The molecule of claim 15, wherein the one or more heavy chain constant regions comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NOs: 92-94.

17. The molecule of claim 16, wherein the one or more heavy chain constant regions comprises the sequence of any one of SEQ ID NOs: 92-94.-297-P93296.WO01 Final specification 19.12.202518. The molecule of any one of claims 1-17, wherein the antigen binding domain comprises a kappa light chain constant region or functional fragment thereof, a lambda light chain constant region or functional fragment thereof, or a combination thereof.

19. The molecule of claim 18, wherein the lambda light chain constant region comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 91.

20. The molecule of claim 19, wherein the lambda light chain constant region comprises the sequence of SEQ ID NO: 91.

21. A molecule comprising a first heavy chain, a second heavy chain, and a first light chain, wherein the first heavy chain and the second heavy chain are non-contiguous, wherein:(a) the first heavy chain comprises a heavy chain variable region (VH), comprising:(i) a heavy chain complementarity determining region 1 (HCDR1) amino acid sequence of any one of SEQ ID NOs: 1-4,(ii) a heavy chain complementarity determining region 2 (HCDR2) amino acid sequence of any one of SEQ ID NOs: 5-12, and(iii) a heavy chain complementarity determining region 3 (HCDR3) amino acid sequence of SEQ ID NO: 13 or SEQ ID NO: 14; and(b) the first light chain comprises a light chain variable region (VL).

22. The molecule of claim 21, wherein the VL comprises:(a) a light chain complementarity determining region 1 (LCDR1) amino acid sequence of any one of SEQ ID NOs: 15-19, SEQ ID NO: 95, or SEQ ID NOs: 130-132,(b) a light chain complementarity determining region 2 (LCDR2) amino acid sequence of any one of SEQ ID NOs: 20-26 or SEQ ID NO: 194, and(c) a light chain complementarity determining region 3 (LCDR3) amino acid sequence of any one of SEQ ID NOs: 27-29.

23. The molecule of claim 21 or 22, wherein the first heavy chain further comprises a first portion of a dimerization domain, wherein the first portion of a dimerization domain linked to the VH.

24. The molecule of any one of claims 21-23, wherein the second heavy chain further comprises a second portion of the dimerization domain.-298-P93296.WO01 Final specification 19.12.202525. The molecule of any one of claims 21-24, wherein the first portion of the dimerization domain and the second portion of the dimerization domain are dimerized.

26. The molecule of any one of claims 21-25, wherein the first heavy chain further comprises a heavy chain constant domain 1 (CHI) linked to the VH.

27. The molecule of claim 23, wherein the CHI is linked to the C-terminus of the VH.

28. The molecule of any one of claims 21-27, wherein the first light chain further comprises a light chain constant domain (CL) linked to the VL.

29. The molecule of claim 28, wherein the CL is linked to the C-terminus of the VL.

30. The molecule of any one of claims 21-29, wherein the first portion of the dimerization module is linked to C-terminus of the VH.

31. The molecule of any one of claims 21-29, wherein the first portion of the dimerization module is linked to C-terminus of the CHI.

32. The molecule of any one of claims 21-31, wherein the first portion of the dimerization module comprises a first immunoglobulin constant region (Fc region) and the second portion of the dimerization module comprises a second Fc region.

33. The molecule of claim 32, wherein the first Fc region, the second Fc region, or a combination thereof is selected from the group consisting of an IgGl Fc region or a functional fragment thereof, an IgG2 Fc region or a functional fragment thereof, an IgG3 Fc region or a functional fragment thereof, an IgGAl Fc region or a functional fragment thereof, an IgGA2 Fc region or a functional fragment thereof, an IgG4 Fc region or a functional fragment thereof, an IgJ Fc region or a functional fragment thereof, an IgM Fc region or a functional fragment thereof, an IgD Fc region or a functional fragment thereof, and an IgE Fc region or a functional fragment thereof.

34. The molecule of claim 32 or 33, wherein the first Fc region, the second Fc region, or a combination thereof comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 93.

35. The molecule of any one of claims 21-34, wherein the first heavy chain comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NOs: 96-111.

36. The molecule of claim 35, wherein the first heavy chain comprises the sequence of any one of SEQ ID NOs: 96-111.-299-P93296.WO01 Final specification 19.12.202537. The molecule of any one of claims 21-36, wherein the second heavy chain comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NOs: 96-111.

38. The molecule of claim 36, wherein the second heavy chain comprises the sequence of any one of SEQ ID NOs: 96-111.

39. The molecule of any one of claims 21-38, wherein the first light chain comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NOs: 112-128, 144-156, or 195-206.

40. The molecule of any one of claims 21-39, wherein the first light chain comprises the sequence of any one of SEQ ID NOs: 112-128, 144-156, or 195-206.

41. The molecule of any one of claims 21-40, wherein the molecule further comprises a second light chain.

42. The molecule of any one of claims 21-41, wherein the second light chain comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NOs: 112-128, 144-156, or 195-206.

43. The molecule of claim 42, wherein the second light chain comprises the sequence of any one of SEQ ID NOs: 112-128, 144-156, or 195-206.

44. The molecule of any one of claims 21-43, wherein the molecule comprises:(a) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112;(b) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 113;(c) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least-300-P93296.WO01 Final specification 19.12.202585%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 114;(d) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 115;(e) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 116;(f) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 113;(g) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 117;(h) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 118;(i) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 119;-301-P93296.WO01 Final specification 19.12.2025(j) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 120;(k) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 121 ;(l) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 98; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 119;(m) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 99; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 117;(n) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 100; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 129;(o) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 101 ; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 113;(p) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO:-302-P93296.WO01 Final specification 19.12.2025101 ; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 126;(q) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 101 ; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 120;(r) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 102; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 127;(s) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 103; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112;(t) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 104; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112;(u) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 103; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 128;(v) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 104; and the first light chain comprising a sequence having at least 75%, at least 80%, at least-303-P93296.WO01 Final specification 19.12.202585%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112;(w) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 105; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 121 ;(x) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 106; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 122;(y) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 107; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112;(z) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 108; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112;(aa) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 109; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 123;(bb) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 110; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 124; or-304-P93296.WO01 Final specification 19.12.2025(cc) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 111; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 125; or(dd) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 111; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 114; or(ee) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 111; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 144; or(ff) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 125; or(gg) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 144; or(hh) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 114; or(ii) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO:-305-P93296.WO01 Final specification 19.12.2025111; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 125; or(jj ) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 145; or(kk) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 146; or(11) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 147; or(mm) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 148; or(nn) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 149; or(oo) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least-306-P93296.WO01 Final specification 19.12.202585%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ IDNO: 150; or(pp) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 151; or(qq) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 152; or(rr) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 153; or(ss) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 154; or(tt) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 155; or(uu) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 113; or-307-P93296.WO01 Final specification 19.12.2025(vv) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 97; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 113; or(ww) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 97; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 153; or(xx) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 97; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 154; or(yy) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 97; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 155; or(zz) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 97; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 156; or(aaa) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 195; or(bbb) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID-308-P93296.WO01 Final specification 19.12.2025NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 196; or(ccc) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 197; or(ddd) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 198; or(eee) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 199; or(fff) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 200; or(ggg) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 201; or(hhh) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at-309-P93296.WO01 Final specification 19.12.2025least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 202; or(iii) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 203; or(jjj ) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 204; or(kkk) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 205; or(111) the first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 206.

45. The molecule of any one of claims 21-44, wherein the molecule comprises:(a) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 112; or(b) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 113; or(c) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 114; or(d) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 115; or-310-P93296.WO01 Final specification 19.12.2025(e) the first heavy chain comprising the sequence of SEQ ID NO: 58; and the first light chain comprising the sequence of SEQ ID NO: 116; or(f) the first heavy chain comprising the sequence of SEQ ID NO: 58; and the first light chain comprising the sequence of SEQ ID NO: 113; or(g) the first heavy chain comprising the sequence of SEQ ID NO: 58; and the first light chain comprising the sequence of SEQ ID NO: 117; or(h) the first heavy chain comprising the sequence of SEQ ID NO: 58; and the first light chain comprising the sequence of SEQ ID NO: 118; or(i) the first heavy chain comprising the sequence of SEQ ID NO: 58; and the first light chain comprising the sequence of SEQ ID NO: 119; or(j) the first heavy chain comprising the sequence of SEQ ID NO: 58; and the first light chain comprising the sequence of SEQ ID NO: 120; or(k) the first heavy chain comprising the sequence of SEQ ID NO: 58; and the first light chain comprising the sequence of SEQ ID NO: 121; or(l) the first heavy chain comprising the sequence of SEQ ID NO: 98; and the first light chain comprising the sequence of SEQ ID NO: 119; or(m) the first heavy chain comprising the sequence of SEQ ID NO: 99; and the first light chain comprising the sequence of SEQ ID NO: 117; or(n) the first heavy chain comprising the sequence of SEQ ID NO: 100; and the first light chain comprising the sequence of SEQ ID NO: 129; or(o) the first heavy chain comprising the sequence of SEQ ID NO: 101; and the first light chain comprising the sequence of SEQ ID NO: 113; or(p) the first heavy chain comprising the sequence of SEQ ID NO: 101; and the first light chain comprising the sequence of SEQ ID NO: 126; or(q) the first heavy chain comprising the sequence of SEQ ID NO: 101; and the first light chain comprising the sequence of SEQ ID NO: 120; or(r) the first heavy chain comprising the sequence of SEQ ID NO: 102; and the first light chain comprising the sequence of SEQ ID NO: 127; or(s) the first heavy chain comprising the sequence of SEQ ID NO: 103; and the first light chain comprising the sequence of SEQ ID NO: 112; or(t) the first heavy chain comprising the sequence of SEQ ID NO: 104; and the first light chain comprising the sequence of SEQ ID NO: 112; or-311-P93296.WO01 Final specification 19.12.2025(u) the first heavy chain comprising the sequence of SEQ ID NO: 103; and the first light chain comprising the sequence of SEQ ID NO: 128; or(v) the first heavy chain comprising the sequence of SEQ ID NO: 104; and the first light chain comprising the sequence of SEQ ID NO: 112; or(w) the first heavy chain comprising the sequence of SEQ ID NO: 105; and the first light chain comprising the sequence of SEQ ID NO: 121; or(x) the first heavy chain comprising the sequence of SEQ ID NO: 106; and the first light chain comprising the sequence of SEQ ID NO: 122; or(y) the first heavy chain comprising the sequence of SEQ ID NO: 107; and the first light chain comprising the sequence of SEQ ID NO: 112; or(z) the first heavy chain comprising the sequence of SEQ ID NO: 108; and the first light chain comprising the sequence of SEQ ID NO: 112; or(aa) the first heavy chain comprising the sequence of SEQ ID NO: 109; and the first light chain comprising the sequence of SEQ ID NO: 123; or(bb) the first heavy chain comprising the sequence of SEQ ID NO: 110; and the first light chain comprising the sequence of SEQ ID NO: 124; or(cc) the first heavy chain comprising the sequence of SEQ ID NO: 111; and the first light chain comprising the sequence of SEQ ID NO: 125; or(dd) the first heavy chain comprising the sequence of SEQ ID NO: 111; and the first light chain comprising the sequence of SEQ ID NO: 114; or(ee) the first heavy chain comprising the sequence of SEQ ID NO: 111; and the first light chain comprising the sequence of SEQ ID NO: 144; or(ff) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 125; or(gg) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 144; or(hh) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 114; or(ii) the first heavy chain comprising the sequence of SEQ ID NO: 111; and the first light chain comprising the sequence of SEQ ID NO: 125; or(jj) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 145; or-312-P93296.WO01 Final specification 19.12.2025(kk) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 146; or(11) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 147; or(mm) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 148; or(nn) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 149; or(oo) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 150; or(pp) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 151; or(qq) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 152; or(rr) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 153; or(ss) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 154; or(tt) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 155; or(uu) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 113; or(vv) the first heavy chain comprising the sequence of SEQ ID NO: 97; and the first light chain comprising the sequence of SEQ ID NO: 113; or(ww) the first heavy chain comprising the sequence of SEQ ID NO: 97; and the first light chain comprising the sequence of SEQ ID NO: 153; or(xx) the first heavy chain comprising the sequence of SEQ ID NO: 97; and the first light chain comprising the sequence of SEQ ID NO: 154; or(yy) the first heavy chain comprising the sequence of SEQ ID NO: 97; and the first light chain comprising the sequence of SEQ ID NO: 155; or(zz) the first heavy chain comprising the sequence of SEQ ID NO: 97; and the first light chain comprising the sequence of SEQ ID NO: 156; or-313-P93296.WO01 Final specification 19.12.2025(aaa) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 195; or(bbb) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 196; or(ccc) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 197; or(ddd) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 198; or(eee) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 199; or(fff) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 200; or(ggg) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 201; or(hhh) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 202; or(iii) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 203; or(jjj ) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 204; or(kkk) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 205; or(111) the first heavy chain comprising the sequence of SEQ ID NO: 96; and the first light chain comprising the sequence of SEQ ID NO: 206.

46. The molecule of claim 44 or 45, wherein the molecule comprises:(a) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112;(b) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID-314-P93296.WO01 Final specification 19.12.2025NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 113;(c) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 114;(d) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 115;(e) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 116;(f) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 113;(g) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 117;(h) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the second light chain comprising a sequence having at least 75%, at least 80%,-315-P93296.WO01 Final specification 19.12.2025at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 118;(i) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 119;(j) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 120;(k) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 58; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 121;(l) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 98; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 119;(m) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 99; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 117;(n) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 100; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 129;-316-P93296.WO01 Final specification 19.12.2025(o) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 101 ; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 113;(p) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 101 ; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 126;(q) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 101 ; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 120;(r) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 102; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 127;(s) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 103; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112;(t) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 104; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112;(u) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID-317-P93296.WO01 Final specification 19.12.2025NO: 103; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 128;(v) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 104; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112;(w) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 105; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 121;(x) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 106; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 122;(y) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 107; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112;(z) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 108; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 112;(aa) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 109; and the second light chain comprising a sequence having at least 75%, at least-318-P93296.WO01 Final specification 19.12.202580%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 123;(bb) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 110; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 124; or(cc) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 111 ; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 125, or(dd) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 111 ; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 114; or(ee) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 111 ; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 144; or(ff) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 125; or(gg) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 144; or-319-P93296.WO01 Final specification 19.12.2025(hh) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 114; or(ii) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 111 ; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 125; or(jj ) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 145; or(kk) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 146; or(11) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 147; or(mm) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 148; or(nn) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID-320-P93296.WO01 Final specification 19.12.2025NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 149; or(oo) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 150; or(pp) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 151; or(qq) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 152; or(rr) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 153; or(ss) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 154; or(tt) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%,-321-P93296.WO01 Final specification 19.12.2025at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 155; or(uu) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 113; or(vv) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 97; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 113; or(ww) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 97; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 153; or(xx) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 97; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 154; or(yy) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 97; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 155; or(zz) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 97; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 156; or-322-P93296.WO01 Final specification 19.12.2025(aaa) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 195; or(bbb) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 196; or(ccc) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 197; or(ddd) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 198; or(eee) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 199; or(fff) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 200; or(ggg) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID-323-P93296.WO01 Final specification 19.12.2025NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 201; or(hhh) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 202; or(iii) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 203; or(jjj ) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 204; or(kkk) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 205; or(111) the second heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and the second light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 206.

47. The molecule of any one of claims 44-46, wherein the molecule comprises:(a) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 112; or-324-P93296.WO01 Final specification 19.12.2025(b) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 113; or(c) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 114; or(d) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 115; or(e) the second heavy chain comprising the sequence of SEQ ID NO: 58; and the second light chain comprising the sequence of SEQ ID NO: 116; or(f) the second heavy chain comprising the sequence of SEQ ID NO: 58; and the second light chain comprising the sequence of SEQ ID NO: 113; or(g) the second heavy chain comprising the sequence of SEQ ID NO: 58; and the second light chain comprising the sequence of SEQ ID NO: 117; or(h) the second heavy chain comprising the sequence of SEQ ID NO: 58; and the second light chain comprising the sequence of SEQ ID NO: 118; or(i) the second heavy chain comprising the sequence of SEQ ID NO: 58; and the second light chain comprising the sequence of SEQ ID NO: 119; or(j) the second heavy chain comprising the sequence of SEQ ID NO: 58; and the second light chain comprising the sequence of SEQ ID NO: 120; or(k) the second heavy chain comprising the sequence of SEQ ID NO: 58; and the second light chain comprising the sequence of SEQ ID NO: 121; or(l) the second heavy chain comprising the sequence of SEQ ID NO: 98; and the second light chain comprising the sequence of SEQ ID NO: 119; or(m)the second heavy chain comprising the sequence of SEQ ID NO: 99; and the second light chain comprising the sequence of SEQ ID NO: 117; or(n) the second heavy chain comprising the sequence of SEQ ID NO: 100; and the second light chain comprising the sequence of SEQ ID NO: 129; or(o) the second heavy chain comprising the sequence of SEQ ID NO: 101; and the second light chain comprising the sequence of SEQ ID NO: 113; or(p) the second heavy chain comprising the sequence of SEQ ID NO: 101; and the second light chain comprising the sequence of SEQ ID NO: 126; or(q) the second heavy chain comprising the sequence of SEQ ID NO: 101; and the second light chain comprising the sequence of SEQ ID NO: 120; or-325-P93296.WO01 Final specification 19.12.2025(r) the second heavy chain comprising the sequence of SEQ ID NO: 102; and the second light chain comprising the sequence of SEQ ID NO: 127; or(s) the second heavy chain comprising the sequence of SEQ ID NO: 103; and the second light chain comprising the sequence of SEQ ID NO: 112; or(t) the second heavy chain comprising the sequence of SEQ ID NO: 104; and the second light chain comprising the sequence of SEQ ID NO: 112; or(u) the second heavy chain comprising the sequence of SEQ ID NO: 103; and the second light chain comprising the sequence of SEQ ID NO: 128; or(v) the second heavy chain comprising the sequence of SEQ ID NO: 104; and the second light chain comprising the sequence of SEQ ID NO: 112; or(w)the second heavy chain comprising the sequence of SEQ ID NO: 105; and the second light chain comprising the sequence of SEQ ID NO: 121; or(x) the second heavy chain comprising the sequence of SEQ ID NO: 106; and the second light chain comprising the sequence of SEQ ID NO: 122; or(y) the second heavy chain comprising the sequence of SEQ ID NO: 107; and the second light chain comprising the sequence of SEQ ID NO: 112; or(z) the second heavy chain comprising the sequence of SEQ ID NO: 108; and the second light chain comprising the sequence of SEQ ID NO: 112; or(aa) the second heavy chain comprising the sequence of SEQ ID NO: 109; and the second light chain comprising the sequence of SEQ ID NO: 123; or(bb) the second heavy chain comprising the sequence of SEQ ID NO: 110; and the second light chain comprising the sequence of SEQ ID NO: 124; or(cc) the second heavy chain comprising the sequence of SEQ ID NO: 111; and the second light chain comprising the sequence of SEQ ID NO: 125; or(dd) the second heavy chain comprising the sequence of SEQ ID NO: 111; and the second light chain comprising the sequence of SEQ ID NO: 114; or(ee) the second heavy chain comprising the sequence of SEQ ID NO: 111; and the second light chain comprising the sequence of SEQ ID NO: 144; or(ff) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 125; or(gg) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 144; or-326-P93296.WO01 Final specification 19.12.2025(hh) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 114; or(ii) the second heavy chain comprising the sequence of SEQ ID NO: 111; and the second light chain comprising the sequence of SEQ ID NO: 125; or(jj) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 145; or(kk) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 146; or(11) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 147; or(mm) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 148; or(nn) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 149; or(oo) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 150; or(pp) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 151 ; or(qq) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 152; or(rr) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 153; or(ss)the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 154; or(tt) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 155; or(uu) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 113; or(vv) the second heavy chain comprising the sequence of SEQ ID NO: 97; and the second light chain comprising the sequence of SEQ ID NO: 113; or(ww) the second heavy chain comprising the sequence of SEQ ID NO: 97; and the second light chain comprising the sequence of SEQ ID NO: 153; or-327-P93296.WO01 Final specification 19.12.2025(xx) the second heavy chain comprising the sequence of SEQ ID NO: 97; and the second light chain comprising the sequence of SEQ ID NO: 154; or(yy) the second heavy chain comprising the sequence of SEQ ID NO: 97; and the second light chain comprising the sequence of SEQ ID NO: 155; or(zz) the second heavy chain comprising the sequence of SEQ ID NO: 97; and the second light chain comprising the sequence of SEQ ID NO: 156; or(aaa) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 195; or(bbb) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 196; or(ccc) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 197; or(ddd) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 198; or(eee) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 199; or(fff) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 200; or(ggg) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 201; or(hhh) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 202; or(iii)the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 203; or(jjj)the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 204; or(kkk) the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 205; or(lll)the second heavy chain comprising the sequence of SEQ ID NO: 96; and the second light chain comprising the sequence of SEQ ID NO: 206.

48. A molecule of any one of claims 1-47, wherein the molecule comprises CDRs determined using the Kabat definition, as set out in Tables 1-5, 7 and 8.-328-P93296.WO01 Final specification 19.12.202549. A molecule of any one of claims 1-47, wherein the molecule comprises CDRs determined using the Chothia definition, as set out in Table 1A or Table IB.

50. A molecule of any one of claims 1-47, wherein the molecule comprises CDRs determined using the IMGT definition, as set out in Table 1A or Table IB.

51. A molecule of any one of claims 1-47, wherein the molecule comprises any one of the sequences from Tables 1-8.

52. A pharmaceutical composition comprising the molecule of any one of claims 1-51 and a pharmaceutically acceptable excipient.

53. A method for enhancing an immune response in a subject, comprising administering an effective amount of the molecule of any one of claims 1-51 or the pharmaceutical composition of claim 52.

54. A method for treating or preventing cancer in a subject, comprising administering an effective amount of the molecule of any one of claims 1-51 or the pharmaceutical composition of claim 52.

55. The method of claim 54, wherein the cancer is selected from the group consisting of: pancreatic cancer, melanoma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine or endometrial cancer, cancer of the oral cavity or pharynx, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small bowel or appendix cancer, salivary gland cancer, thyroid gland cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, and cancer of hematological tissues.-329-P93296.WO01 Final specification 19.12.2025

Images